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Preface 
The experimental work described in this thesis was conducted at the Africa Health Research 
Institute (formerly KwaZulu-Natal Research Institute for Tuberculosis and HIV- K-RITH), Nelson R 
Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, from February 2015 to 
December 2016, under the supervision of Dr Emily Beth Wong and Prof Thumbi Ndung’u. 
This work has not been submitted in any form for any degree or diploma to any other tertiary institution, 
where use has been made of the work of others, it is duly acknowledged in the text. 
Abstract 
Introduction: Tuberculosis is the leading cause of mortality in HIV-infected individuals 
worldwide.  HIV-infected individuals have increased risk of developing active tuberculosis even at high 
CD4 T-cell counts and while undergoing effective antiretroviral therapy. The mechanisms that result in 
anti-TB immune dysfunction in HIV-infected people are not well understood.  Previous studies have shown 
that a type II (IFN-γ) interferon-driven vitamin D-dependent antimicrobial pathway in monocytes and 
macrophages is important for the control of Mycobacterium tuberculosis (M. tb) growth in vitro. Notably, 
acute and chronic HIV infection are associated with high levels of type I interferons, specifically interferon 
alpha 2a (IFNα2a). Type I interferon has been shown to be upregulated during M. tb infection and has been 
found to be detrimental to M. tb control.  We, therefore, hypothesised that HIV-1 infection induces an 
interferon-driven dysregulation of the vitamin D-dependent antimicrobial pathway in monocytes, which 





groundwork that will allow a comprehensive assessment of this hypothesis in a monocytic cell line and in 
primary human peripheral blood samples. 
Methods: In this study, a one-plate quantitative polymerase chain reaction (qPCR) protocol for the 
reliable detection of Cytochrome P450 family 27 subfamily B member 1 (CYP27b1), cytochrome P450 
family 24 subfamily A member 1 (CYP24a1), Cathelicidin (CAMP), Beta-defensin (DEFB4), and Vitamin 
D receptor (VDR) by the LightCycler 480 (Roche) was optimised for the human monocyte monocytic cell 
line (THP-1).  The assays were also used to evaluate the expression of these transcripts in primary human 
peripheral CD14+ monocytes isolated using immunomagnetic separation from healthy donors (n=3). Cells 
were stimulated with recombinant human interferon gamma (rhIFNγ) (2,000 IU/mL) and recombinant 
human interferon alpha (rhIFN2a) (2,500 IU/ mL) for 24 hours. The impact of Type I and Type II interferons 
on gene expression were calculated using the Pfaffl equation to compare expression of genes of interest 
(normalised to GAPDH) between stimulated and unstimulated conditions.  
Results: Quantitative PCR protocols were developed to reproducibly measure CAMP, VDR and 
CYP27b1 in THP-1 cells and primary human monocytes.  Basal levels of these three transcripts were 
expressed at similar levels in THP-1 cells and primary monocytes relative to GAPDH, however, CYP27b2 
was notably less expressed in CD14+ cells relative to THP-1 cells.  DEFB4 and CYP24a1 could not be 
detected in THP-1 cells1s but were reproducibly detectable in primary human monocytes.   
Comparative analysis of THP-1s and healthy donor CD14+ monocytes after stimulation with type I and II 
interferon showed varying modulation of the genes of interest. In THP-1s IFNα2a had the expected 
inhibitory effect on the three detectable transcripts of interest (CAMP, CYP27b1 and VDR). Stimulation 
with IFNγ resulted in the unexpected down-regulation of CAMP and CYP27b1. In healthy donor CD14+ 
monocytes stimulated with IFNγ, CAMP, CYP24a1, CYP27b1 and DEFB4 were all significantly 
upregulated. IFNα2a resulted in a trend towards up-regulation of CAMP, CYP24a1, CYP27b1 and DEFB4.  






Conclusions: Stimulation with exogenous recombinant type I/II interferon showed unexpected 
programs of gene modulation. Interferon gamma stimulations generally upregulated key genes in the 
vitamin D-dependent antimicrobial pathway, supporting the hypothesis that type II interferon signalling 
contributes to the protective upregulation of antimicrobial peptides. Unexpectedly, interferon alpha elicited 
a non-significant upregulation of all vitamin D-antimicrobial peptides and associated regulatory transcripts 
in healthy donor peripheral monocytes, a finding that contrasts to the reported literature and requires further 
exploration.   
Our study revealed significant differences in the expression and modulation of key genes in the vitamin D-
dependent antimicrobial pathway between immortalised THP-1 monocytic cells and primary human 
monocytes. It is possible that the undetectable levels of CYP24a1 and DEFB4 in THP-1 cells are due to 
lack of bioavailable vitamin D. This hypothesis is supported by the specific, detectable expression of both 
transcripts in CD14+ monocytes from healthy donors, which were presumably vitamin D replete. 
Modulation of vitamin D levels was outside the scope of this project and further study is needed to explore 
this issue.  
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1. CHAPTER ONE: Introduction and Literature Review 
1.1 Human Immunodeficiency Virus (HIV) 
Human immunodeficiency virus, or HIV, is a lentivirus of the Retroviridae family. HIV specifically 
infects human immune cells expressing the CD4 protein on the cell surface (Dalgleish et al., 1984). This 
targeted infection leads to a progressive worsening of the immune system, allowing for the subsequent 
acquisition of opportunistic infections. In the absence of antiretroviral therapy, infection with the virus 
almost always results in the development of the acquired immunodeficiency syndrome (AIDS) (Sharp and 
Hahn, 2010). HIV is primarily transmitted via the exchange of infected blood or other bodily fluids. The 
most common routes of transmission are through sexual intercourse, contaminated needles during drug use 
and mother to child transmission during gestation and birth. Stigma and societal vulnerability have driven 
high rates of infection in certain key populations such as homosexuals, intravenous drug users, transgender 
people and adolescents. These key populations thus remain a significant driver of infection in high resource 
settings. However, in the sub-Saharan Africa setting, the HIV epidemic is a generalised epidemic primarily 






Figure 1: Worldwide Estimates of People Living with HIV, 2013 (WHO, 2014). Sub-Saharan Africa has 
the highest burden of HIV infection worldwide (±25 mil infections), followed by South-East Asia and then 
North and South America. 
The discovery of HIV occurred approximately thirty years ago when doctors observed an 
unexplainable increase in the occurrence of Kaposi’s sarcoma and other opportunistic infections in 
otherwise young, previously healthy, homosexual men in both New York City and Los Angeles (Barre-
Sinoussi et al., 2013, Friedman-Kien et al., 1981). The predominant feature in the men was depression of 
adaptive and innate immune control during microbial challenge leading to increased incidence of 
opportunistic diseases and other microbial infections (Friedman-Kien et al., 1981). The occurrence of these 
opportunistic infections due to depressed immunity in predominantly gay men initially prompted the idea 
that this unexplained condition was only experienced by homosexual males. However, this was later proved 
not to be the case when similar symptoms were observed among intravenous drug users and blood 
transfusion recipients (Barre-Sinoussi et al., 2013). During this period, the condition was referred to as 
autoimmune deficiency syndrome, or AIDS, by the Centres for Disease Control (CDC) of the United States. 
In 1982, the first occurrence of mother to child transmission of AIDS was observed which led to the first 





led scientists and doctors at the time to conclude that AIDS was caused by some unknown transmissible 
agent via blood and other possible body fluids rather than lifestyle choice (Notes, 1982).  
The controversial idea that AIDS was caused by a retrovirus was first proposed to Robert Gallo, a 
prominent virologist, whose work led to the discovery of the human T-cell leukaemia virus (HTLV-1 and 
-2), the only known human retroviruses at the time (Montagnier, 2002). Gallo’s group also pioneered the 
field in cytokine discovery by characterising and utilising interleukin 2 (IL-2) for the in vitro culture of 
human T-cells (Montagnier, 2002, Morgan et al., 1976). This provided the platform and opportunity to 
characterise hypothetical human T-cell tropic retroviruses ex vivo. This was later achieved by Luc 
Montagnier’s research group at the Pasteur Institute in France (Montagnier, 2002). The group was 
fortuitously placed to tackle this particular question due to their interest in the search for lymphotropic 
retroviruses found in T cells (Barre-Sinoussi et al., 2013). In 1983, the first traces of reverse transcriptase 
were identified from a lymph node biopsy sourced from a homosexual male in the USA which was 
processed into a single cell suspension and cultured with T-cells using IL-2 (Montagnier, 2002). In the time 
between 1983 and 1984 Gallo’s group, as well as Montagnier’s group, published data firmly supporting the 
hypothesis that HIV was the cause of AIDS. This discovery accelerated the field of HIV research and 
allowed for the sequencing of the HIV genome in 1985, the identification of gp41 and the discovery that 
HIV-infected T-cells by using CD4 as its receptor (Montagnier, 2002, Dalgleish et al., 1984). Two years 
later, diagnostics for the detection of HIV-1 were developed, allowing screening of the blood supply to 
prevent transfusion-related transmission of the infection  (Montagnier, 2002). 
Structurally, HIV is generally spherical containing two single strands of RNA (ssRNA) 
encapsulated in a conical capsid composed of viral protein (Briggs et al., 2003). The two single-stranded 
RNA strands are bound to nucleocapsid proteins, viral proteins and enzymes critical for replication and 
maturation of HIV such as reverse transcriptase, integrase and protease (Briggs et al., 2003). Surrounding 





a host cell, containing glycoproteins gp120 and gp41 which enclose the entire capsid to form a mature 
infectious virion (Briggs et al., 2003).  
 
Figure 2: Estimated Deaths due to HIV/AIDS by WHO Region, 2013 (WHO, 2014). Africa has the highest 
estimated number of deaths due to HIV/AIDS worldwide. This is closely followed by India and the 
Americas. 
Globally HIV affects more than 35 million people (Figure 1) with the bulk of the infections in 
developing countries, especially Africa and South Asia. In 2013, global deaths attributed to the HIV/AIDS 
were more than 1.5 million with the largest portion of AIDS-related mortality due to Mycobacterium 






Figure 3: Phylogenetic Diversity of HIV and SIV (Calef, 2008). 
HIV is characterised by both a high mutation rate, retroviral recombination and high replication 
rate which facilitates a high degree of genetic variability (Hemelaar, 2012, Smyth et al., 2012). As such, 
there exists a large diversity of HIV worldwide (Figure 3). There are two major types of HIV namely; HIV-
1 and HIV-2. In general, HIV-1 has higher virulence, infectivity and is vastly more common worldwide 
representing approximately 95% of all infections (Sharp and Hahn, 2010).  In contrast, HIV-2 is found 
mostly in West Africa and in areas with a historical link to West Africa (Hemelaar, 2012). HIV-1 can further 
be subdivided into groups M, N, O and P and in the case of group M, into subgroups (A-K) (Figure 3) 
(Hemelaar, 2012, Vallari et al., 2011). Each group of HIV-1 is hypothesised to represent independent 
transmissions of simian immunodeficiency virus (SIV) strains into human populations via non-human 
primate populations (Hemelaar, 2012, Vallari et al., 2011). Recombination of different functional subtypes 
is also common resulting in circulating recombinant forms, or CRFs, which further increase the diversity 
of HIV strains. Group M HIV-1 viruses are the most common, forming approximately 90% of cases and 
therefore primarily responsible for the acquired immunodeficiency syndrome pandemic.  However, the 





geographically, however, increased global travel has allowed for the international spread of the various 
subtypes into previously non-endemic areas. Group N infection was initially observed exclusively in 
Cameroon in a small number of individuals who were tested (Hemelaar, 2012). Group O HIV-1 is also 
closely associated with the Cameroon and is rarely seen in regions of the world other than West Africa 
(Hemelaar, 2012). Group P HIV-1 virus was first identified in a woman living in France, who had 
previously lived in the Cameroon (Vallari et al., 2011). The viral sequence was found to be more similar to 
gorilla SIV rather than chimpanzee SIV (Hemelaar, 2012). 
Fortunately, the development of combination antiretroviral treatment (cART), has significantly 
improved the prognosis of HIV-infected persons worldwide allowing them to lead long fulfilling lives 
(Smyth et al., 2012). However, the persistence of HIV in viral reservoirs even in the face of ART means 
that although the immune system (CD4 count) may be reconstituted to near normal levels, an infected 
individual will have to remain on ART for the remainder of their lives.  
1.2 Tuberculosis (TB) 
Mycobacterium tuberculosis, also known as Koch’s bacillus, is a rod-shaped bacterium which was 
first discovered by Robert Koch in 1882 (Koch, 1882). It is a slow growing, aerobic bacterium which affects 
human hosts, and is not found in other species or abiotic environments (National Institute of Allergy and 
Infectious Disease, 2012). Tuberculosis (TB) is an ancient disease caused by a loss of host immune control 
of Mycobacterium tuberculosis (M. tb) and is the leading infectious killer worldwide (Muller et al., 2014, 
WHO, 2015, WHO, 2016a). Mycobacterium tuberculosis is an extremely infectious bacterium transmitted 
by inhalation of aerosolized respiratory secretions, with bacteria inhabiting tiny microscopic droplets of an 








Figure 4: Global TB Incidence Rates, 2015 (World Health Organization, 2016a).  
 
Figure 5: Estimated TB deaths excluding those attributed to HIV co-infection, 2015 (World Health 
Organization, 2016a). 
Mycobacterium tuberculosis infection occurs worldwide; however, TB is most prevalent in 





due to TB in 2015 (excluding cases in which the patients had HIV infection) demonstrating that the 
mortality burden is disproportionately borne by developing countries with particularly severe mortality 
rates in Central-Southern Africa and Asia. It is estimated that around 1.6-2.0 million people die from TB 
annually (WHO, 2016a). Globally, about 90% of tuberculosis cases occur in adults and 60% of TB mortality 
occurs in men. (World Health Organization, 2015, World Health Organization, 2016a). 
Mycobacterium tuberculosis-infected persons who have not progressed to disease are termed 
‘latently infected’ and have a positive tuberculin skin test (PPD Test) whilst having an absence of 
respiratory symptoms and negative sputum smears (Miller et al., 2000). In general, the bacterium can 
remain dormant and non-infectious in a healthy person for years and may become activated during immune 
suppression (Rappuoli and Aderem, 2011, National Institute of Allergy and Infectious Disease, 2012). It is 
estimated that more than two billion (approximately 1 in 3 people worldwide) people are infected with 
latent TB worldwide; of this 10 % will progress to active TB in their lifetimes (Rappuoli and Aderem, 2011, 
WHO, 2016a). The factors which lead to progression of latent to active disease are incompletely understood 
but include immune suppression (HIV infection, diabetes and tumour necrosis factor (TNF) neutralisation 
therapies) (Barry et al., 2009).  In situations of repeated/prolonged exposure to environments in which a 
high degree of M. tb is present, such as clinics, prisons and countries with an extremely high prevalence of 
M. tb infection, it can be difficult to distinguish progression of latent infection from re-infection (Miller et 
al., 2000, National Institute of Allergy and Infectious Disease, 2012, WHO, 2015). 
Once M. tb infection progresses to disease, it can infect different sites in the body causing 
pulmonary TB (in the lungs), TB meningitis (in the central nervous system) or disseminated TB (in any 
other region of the body e.g. bones, lymph nodes and the joints). The most common form of the disease in 
HIV-uninfected people is pulmonary TB in which M. tb infection results in lung cavities and presents with 
chest pain, coughing and blood in the sputum (Miller et al., 2000, National Institute of Allergy and 
Infectious Disease, 2012). Other symptoms include fever, night sweats and weight loss (Miller et al., 2000, 





1.3 TB/HIV Co-infection 
Recent genetic evidence suggests that TB has afflicted homo sapiens for as long as 15 000 years, 
whilst archaeological evidence suggests an even longer interaction (since the Neolithic period) supporting 
the hypothesis of historical coevolution (Muller et al., 2014). In the 1700-1900s, TB was a major cause of 
morbidity and mortality death for many areas of Europe where its rapid spread was facilitated via the high-
density living conditions. The development of antimicrobial drugs coupled with improved public health 
practices resulted in a significant decline (approximately 45%) in the number of active tuberculosis cases 
in the 20th century.   
The emergence of HIV/AIDS in the early 1980s led to a significant resurgence of active 
tuberculosis due to immune suppression. Globally, approximately 84% of new TB cases occurs in HIV 
negative individuals, however, in certain countries, HIV infection has been found to be major driver of new 
infection within these sensitive populations (WHO, 2016a). With relevance to this study, upwards of 50% 
of new cases of TB are reported among HIV-infected individuals irrespective of antiretroviral treatment 
status in Sub-Saharan Africa (Figure 7) (Rappuoli and Aderem, 2011, WHO, 2015, WHO, 2016a). Per the 
World Health Organization, TB is the greatest cause of death for HIV-positive populations worldwide and 
the deadliest infectious killer globally (Rappuoli and Aderem, 2011, WHO, 2015). In 2013 alone, it is 
estimated that approximately 9 million people worldwide developed TB of which 1.5 million people died 
of the disease (WHO, 2014). Of those, 360 000 people were HIV positive (WHO, 2014). The emergence 
of multidrug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of TB in HIV-infected 
patients have further exacerbated the problem leading to an increase in morbidity and mortality worldwide 
in spite of modern drug treatment (Groschel et al., 2014, Brust et al., 2011). In 2015, 11% of all TB-related 
deaths in Africa and South East Asia were observed in HIV-positive individuals (WHO, 2016a). 
Figure 6 illustrates the relationship between HIV infection, CD4+ cell count and TB risk over time 
following the onset of HIV infection. An inversely proportional relationship between CD4+ cell count and 





counts are still relatively preserved (>500 cells/µl) (Havlir et al., 2008). The exact mechanisms of how HIV 
exacerbates TB sensitivity remains a key gap in the knowledge of the field. 
 
Figure 6: Schematic of Risk of TB and Change in CD4+ Cell Count from Onset of HIV Seroconversion 
(Havlir et al., 2008). After HIV seroconversion and before the use of ART, TB risk increases exponentially 







Figure 7: Estimated HIV Prevalence in New/Relapse TB Cases in 2015 (World Health Organization, 
2016a). In southern Africa, upwards of 50% of new cases of TB are in patients already living with HIV. 
TB remains the leading killer of HIV-infected individuals worldwide and much work remains to 
be done at both the political as well as basic research level to understand and stop the interactions of these 
two deadly infectious diseases.  
1.4 Cytokines are associated with HIV infection.  
During acute infection with HIV, the virus induces a global upregulation of immune regulatory 
cytokines in a phenomenon termed a "cytokine storm." (Figure 8) Although levels wane following acute 
infection, cytokines persist at elevated levels through chronic infection and never return to pre-infection 
baseline levels (Stacey et al., 2009). Cytokines are important cell signalling proteins which drive the 
ontogeny of immune cell populations as well as facilitate proper host immune responses, both humoral and 







Figure 8: Cytokine Storm-induced by Acute HIV-1 infection (Stacey et al., 2009). During acute infection, 
a cytokine storm is induced. Many cytokines persist at elevated levels through to chronic phase of infection. 
Of importance in mounting an effective immune response to invading pathogens is the induction 
of interferons during viral and bacterial challenge. 
1.4.1 Interferon gamma (IFN-γ) 
Interferons, as the name implies, are a diverse group of proteins which were initially discovered 
and named due to their ability to “interfere” with microbial infection, enabling clearance of pathogens by 
the host immune system (Schroder et al., 2004). Owing to varying homology and receptor binding sites, 
interferons are grouped into three groups; namely Type I, Type II and the recently discovered Type III 
(Schroder et al., 2004, Hermant and Michiels, 2014). Type III IFN has been implicated to be important in 
the antiviral response at barrier mucosal sites whilst avoiding the deleterious pathogenic risk associated 
with type I IFN antiviral activity (Wack et al., 2015). The effect or action of Type III interferons are beyond 
the scope of this thesis, as such, thus further discussion of interferons will be limited to the better understood 





in the innate immune system. Type II IFNs were associated with antibacterial/antimycobacterial activity 
and type I IFNs with antiviral activity. Although this is largely true, it is now known that most cases of 
pathogen clearance require a delicate, coordinated expression of both type I/II IFNs for an adequate immune 
response to be mounted. 
There is only Type II interferon - interferon gamma (IFN-γ) which is expressed by CD4+ and CD8+ 
T cells.  Natural killer cells and innate lymphocytes also express IFN-γ in response to bacterial infection 
(Schroder et al., 2004, Cooper et al., 2011). Knockout experiments in the murine model, for both IFN-γ and 
the receptor to which it binds, have been shown to cause no developmental defects (Huang et al., 1993). 
However, when challenged with viral and bacterial pathogens, there was a significant reduction in the 
resistance to infection (Schroder et al., 2004, Huang et al., 1993). This particularly true for mycobacteria 
infection in both mice models and studies of human families with inherited mutations in these sites (Cooper 
et al., 2011, Jouanguy et al., 1997, Jouanguy et al., 1996). 
During acute HIV infection, the levels of IFNγ have been observed to significantly increase, and 
whilst they drop down as the infection progresses, the concentration in the periphery remains elevated in 
comparison to HIV-uninfected individuals.  
1.4.2 Interferon alpha (IFNα2a) 
Type I interferons were first described in a publication by Isaacs and Lindenmann nearly 52 years 
ago and have historically been primarily implicated in defence or protection during the viral invasion of the 
host (Trinchieri, 2010, Isaacs and Lindenmann, 1957, Hoofnagle et al., 1986). Intravenous IFNα2a 
treatment has been used successfully to treat a number of viral infections ranging from hepatitis B to human 
papillomavirus (HPV) (Nieminen et al., 1994, Hoofnagle et al., 1986). In fact, exposure of particular cells 
to this interferon induces a protective antiviral state which limits productive viral proliferation. Type I IFN 
is expressed by almost all cells in the body in response to free viral nucleic acid. There are 5 main types of 
IFN type I with multiple subtypes within each group. Of these, interferon alpha 2a, class II alpha helical 





infection and has been hypothesised to have significant implications for immune functioning during 
HIV/TB coinfection (Doyle et al., 2015, Gomez et al., 2015, Hardy et al., 2013, Ottenhoff et al., 2012). 
Like IFNγ, IFNα2a persists at an elevated level in people with chronic HIV infection which may modulate 
TB pathogenesis (Stacey et al., 2009).  
In contrast to the generally protective role of type I interferons in viral infection, during bacterial 
infections, these interferons have a less clear role. Often, upregulation of type I interferon has a negative 
effect on many cells ability to control the infection of the invading pathogenic bacterium (Decker et al., 
2005). However, this is not always true. In certain cases of bacterial infection, such as Chlamydia 
trachomatis, Chlamydophila pneumoniae and Legionella pneumophilatype type I interferon has been 
shown to inhibit replication ex vivo and thus abrogate pathogenesis both directly and indirectly (de la Maza 
et al., 1985, Buss et al., 2010, Plumlee et al., 2009). However, type I interferon is thought to fail to elicit 
protective responses against mycobacterial infection (Teles et al., 2013). 
Exogenous application of type I interferon has been shown by several groups to encourage the 
growth of mycobacteria and exacerbate disease outcomes in human macrophages and monocytes 
(Bouchonnet et al., 2002). Redford et .al showed in mice that even temporary viral infection with influenza 
A correlated with an impairment of M. tb control in a type I IFN dependent manner, which may imply long-
term impairment for patients suffering from chronic viral diseases such HIV-1 (Redford et al., 2014). In 
mice, inhibition of the IFNα2a receptor allowed for greatly reduced bacterial loads of Mycobacterium 
tuberculosis relative to wild-type mice and better disease outcome (Antonelli et al., 2010, Manca et al., 
2001). Interestingly, in mouse models (severe combined immune deficiency (SCID)) infected with a 
hypervirulent clinical strain of M. tb, researchers reported significantly upregulated levels of type I 
interferon mRNA from dissected lung samples which was in turn correlated with increased mortality during 
early disease relative to wild-type mouse controls (Manca et al., 2001, Manca et al., 2005).  These studies 
suggest that type I interferons may play a mechanistic role in the decreased anti-mycobacterial immunity 





1.4.3 The Complex Interplay of Type I/II Interferon 
Overall, it proper immune priming and clearance of invasive pathogens via the innate and adaptive 
immune system is facilitated through an interactive, coordinated expression of both types I and II 
interferons depending on the nature of the microbial challenge. The ‘yin and yang’ of type I/II IFNs, 
particularly the dysregulation of this balance during coinfection is hypothesised to affect the immune 
system's ability to clear a pathogen over the course of infection. The nature of interactions between these 
cytokines and its impact on infection outcome is still hotly debated (Decker et al., 2005). Further, the 
importance of interferon balance to the clearance of specific pathogens remains unclear. There is evidence 
that during certain infections, the two types of cytokines work synergistically to clear or control pathogens.  
In contrast, it has been demonstrated that in certain infections including mycobacterial, type 1 interferons 
may abrogate the protective effects of type II interferon leading to worsening of immune control and 
progression to clinical disease (Bouchonnet et al., 2002, Teles et al., 2013). 
1.5 Toll-like Receptors (TLRs)  
Toll-like receptors, or TLRs, are a varied group of membrane spanning proteins which can 
recognise a diverse range of chemical stimuli such as pathogen-associated molecular patterns (PAMPs) as 
well as chemical markers of tissue damage (Christmas, 2010, Kawai and Akira, 2010). Recognition of these 
molecules results in the establishment of the immune response, initially innate and later adaptive. These 
TLRs are found predominantly in cells most likely to be challenged by microbial pathogens, such as 
macrophages, monocytes, dendritic and other professional antigen presenting cells (APCs) which can 
mount an immediate innate immune response. 
In mammals, thirteen TLRs have been discovered. In humans, nine TLRs are important, with TLR 
11, 12 and 13 lost from the genome (Hidmark et al., 2012, Kawai and Akira, 2010). TLRs 1-2 and 4-6 are 
found on the outer surface of the cell and respond primarily to bacterial antigen stimulation. The remaining 
TLRs, 3 and 7-9, are found intracellularly on the surface of endosomes and primarily recognise pathogenic 





binding of antigen to the pattern recognition receptor (PRR) of the TLR, two major signalling pathways 
become activated (Figure 9) (Kawai and Akira, 2010). The major pathway results in the activation of 
nuclear factor-κB and the mitogen-activated protein kinases p38 and JNK. The other pathway (primarily 
activated through TLR 3/4) allows for the activation of nuclear factor-κB as well as IRF3, which allows for 
additional anti-viral/bacterial genes to be activated resulting in the downstream expression of protective 
cytokines such as Type I interferons and other inflammatory cytokines (Kawai and Akira, 2010). These 
protective cytokines are essential for the modulation of successful innate and adaptive immune responses 
during microbial challenge (Kawai and Akira, 2010). 
 
Figure 9: Generalised cell model showing the all available TLRs and associated biochemical cascades 





1.6 Monocytes, Macrophages and the Innate Immune System 
1.6.1 Challenges in TB vaccine design and the need to understand mechanisms of innate anti-TB 
immunity 
A universally efficacious vaccine applicable to all age groups is urgently needed to prevent and 
control tuberculosis. Efforts to develop a novel vaccine have been hampered by the limited understanding 
of the mechanisms of protective immunity against M.tb. The Bacillus Calmette-Guerin (BCG) vaccine has 
been in use for many years with vaccinations carried out in early childhood and with varying success rate 
of 0 to 80% (Andersen and Doherty, 2005, Rappuoli and Aderem, 2011). Research has shown that the BCG 
vaccine does have the ability to protect against disseminated disease and death in young children and 
infants, however; protection against pulmonary disease was found to be highly variable (Andersen and 
Doherty, 2005, Rappuoli and Aderem, 2011). BCG however, is unable to protect adults against pulmonary 
or chronic infection (Rappuoli and Aderem, 2011).  
The first new vaccine candidate since the discovery and implementation of BCG almost 50 years 
ago was an inoculant called MVA85A. (Ndiaye et al., 2015, Tameris et al., 2013). The candidate vaccine 
was synthesised from a strain of Vaccina Ankara virus which expressed antigen 85A from M. tb. Research 
on this vaccine candidate prior to clinical trials was promising, and MVA85A proceeded to clinical trials 
in both adults and infants (Ndiaye et al., 2015, Tameris et al., 2013). The vaccine was designed to be used 
as a viable boost following vaccination with BCG and was shown to have good immunogenicity in animal 
studies. Although the vaccine induced satisfactory cell-mediated host immune responses in both adults and 
infants, ultimately the vaccine was found to be non-protective as no significant difference was observed 






Figure 10: Incidence of TB acquisition in adults receiving the MVA84A vaccine relative to those who 
received placebo. There was no significance difference observed between the test group and the placebo 
group (Ndiaye et al., 2015). 
 
Figure 11:  Incidence of TB Acquisition in Infants receiving the MVA84A vaccine relative to those who 
received placebo. There was no significance difference observed between the test group and the placebo 





The failure of MVA85a has highlighted the need for a better understanding of host defence 
mechanisms of natural anti-TB immunity. Animal studies suggest that innate immune cells such as 
macrophages and monocytes may play an important role in anti-tuberculous immunity (Modlin and Bloom, 
2013).  Furthermore, the observation that HIV-1 infected people, irrespective of disease stage or treatment 
status, are at significantly higher risk (26-30 times) for M. tb. infection and active disease suggest an 
irreversible loss of anti-TB immunity during coinfection with HIV (WHO, 2016b). The underlying 
mechanisms of this vulnerability remain largely undetermined. Thus, a better understanding of innate 
mechanisms of protective immunity against TB and a detailed understanding of the impact of HIV on anti-
TB immunity may be a plausible pathway to the development of an effective vaccine or immunotherapy.    
1.6.2 Vitamin-D Dependant Antimicrobial Peptides and their Role in Innate Immune Defence 
Antimicrobial peptides or AMPs, (bactenecins, cathelicidins and defensins) are the ancient 
armaments of innate immune defence against microbial challenge in a number of species (Hazlett and Wu, 
2011). There have been over eight hundred AMPs discovered from a range of living organisms, both 
prokaryotic and eukaryotic (Hazlett and Wu, 2011). In general, the peptides are named in accordance with 
their secondary structures; beta-stranded, alpha-helical, beta-hairpin and extended (Dhople et al., 2006). 
They are often called cationic AMPs due to the high density of positively charged amino acids present in 
their varying structures (Hazlett and Wu, 2011).  
AMPSs are induced when the immune system recognises invading pathogens via toll-like receptors 
to control infection and prevent disease. They also have similar modes of protective activity despite their 
structural differences, with the positively charged portions of their structure interacting with the negatively 
charged regions on microbe cell walls/membranes leading to increased membrane fluidity and cell death 
(Hazlett and Wu, 2011). Thus, the expression and protective ability of these antimicrobial peptides depend 
largely on proper toll-like receptor activation post agonist recognition and the co-secretion of 
immunoregulatory cytokines by other cytokine-secreting leukocytes to mount an efficient immune response 





1.6.2.1 Cathelicidin (LL-37)  
Cathelicidins are one of the primary arms of defence for prokaryotic and eukaryotic organisms. A 
distinguishing characteristic of cathelicidins is a much-conserved cathelin domain. Cathelicidin or as it 
known in its shortened forms; LL-37 or CAMP, is the only known human cathelicidin-derived antimicrobial 
peptide (Vandamme et al., 2012, Durr et al., 2006). The killing ability of cathelicidin, or LL-37, is largely 
due to its secondary structure (Vandamme et al., 2012, Durr et al., 2006). Cathelicidin interacts with the 
cell membrane of the pathogen either as a monomer or as complex oligomers. Lying parallel to the surface 
of the pathogen, cathelicidin binds to the negatively charged phospholipids on the surface of the pathogen. 
At a particular concentration of bound cathelicidin to the surface, positive curvature strain is induced. This 
is ameliorated by the movement of the cathelicidin peptides from the outer cell wall into the periplasmic 
region of the cell wall where cathelicidin then binds to the inner membrane of the pathogen. The movement 
of AMP from the outside of the cell to the inner membrane results in the formation of minute pores which 
disrupt the balanced homoeostasis of the membrane and cell wall biogenesis leading to cell death 
(Vandamme et al., 2012). Interestingly, cathelicidin has also been reported to have the effect of decreasing 
the ability of bacteria to infect cells by decreasing a cell's permeability (Byfield et al., 2011).  
Cathelicidin has been shown in the literature to be effective against multiple microbial pathogens 
ranging from bacteria to fungi and is highly expressed at the site of inflammation during infection, thus this 
antimicrobial peptide is an important contributor in the clearance of invasive pathogens. Mouse cathelicidin 
knock-out studies reported a marked sensitivity to microbial infection, and increase in mortality and 
morbidity (Sonawane et al., 2011). To further substantiate the protective ability of LL-37, mice infected 
with drug-sensitive H37Rv and MDR strain of M. tb were dosed with human cathelicidin (LL-37 or 
CAMP), murine cathelicidin (CRAMP) and synthetic cathelicidin-like compounds. In all cases, the 
treatments reduced they mycobacterial load three to tenfold (Rivas-Santiago et al., 2013). 
Cathelicidin has also been reported to be moderately protective against certain viral infections such 





through a direct interaction with the envelope region of an infective virion. Certain fragments of LL-37 are 
also able to directly block the ability of HIV-1 to reverse-transcribe its RNA (Wong et al., 2011).  
 
Figure 12: Crystal Structure of Cathelicidin (Vandamme et al., 2012). 
1.6.2.2 Beta-Defensin 2 
Defensins are cationic cysteine-rich peptides of relatively small size and are characterised by a 
beta-sheet structure bonded by three disulphide bonds formed of 6 cysteine residues (Figure 6) (Hazlett and 
Wu, 2011). Although structurally similar, defensins can be segregated into two main groups namely, alpha 
and beta defensins (Hazlett and Wu, 2011). Alpha-defensins are abundant primarily in the granules of 
neutrophils, whilst beta-defensins are slightly larger peptides which are produced in mucosal epithelial cell 
populations such as macrophages, monocytes and dendritic cells (Hazlett and Wu, 2011). Defensins are 
highly water soluble; however, they also have the ability to interact with the hydrophobic lipid structure of 
invading bacteria/mycobacteria (Hazlett and Wu, 2011).  
During microbial challenge, innate immune cells very rapidly release defensins at the site of 
pathogen recognition. The rapid secretion of defensins into the cellular environment is hypothesised to limit 
pathogen replication/invasion as well as facilitate downstream adaptive immune responses (Hazlett and 
Wu, 2011). Twenty-eight different beta-defensin genes are thought to exist within the human genome; 





1 to 4 remain the most researched antimicrobial peptides of this type. Beta-defensin 2/3, in particular, are 
upregulated by bacterial challenge or their products such as lipopolysaccharide (LPS) and other cytokines 
such as TNF-α (Hazlett and Wu, 2011).  
Ex vivo experiments involving the transfection of human monocyte-derived macrophages with 
mRNA encoding beta-defensin 2 enhanced the macrophages’ ability to restrict the growth of M. tb, 
suggesting a role for DEFB4 in mycobacterial defence.(Kisich et al., 2001).   
 
Figure 13: Crystal Structure of Beta-Defensin 2 (Protein Data Bank, 2001) 
The expression of both cathelicidin and beta-defensin 2 are under the control of a Vitamin-D 
dependent antimicrobial pathway in a range of phagocytes (Modlin and Bloom, 2013, Liu et al., 2006, Liu 
et al., 2007). 
1.6.3 Innate Protection: Vitamin D Dependent Antimicrobial Pathway 
The innate immune response is the body’s first response to invading pathogens. It can be thought 
of as having three main arms which provide initial and immediate protection; physical, cellular and humoral 
(Hazlett and Wu, 2011). Protective barriers such as the skin or other epithelial layers constitute the physical 
aspect of innate protection and the first major obstacle which needs to be overcome by an invading pathogen 
to achieve successful infection (Hazlett and Wu, 2011). Humoral protection is facilitated via the secretion 





facilitating cell death (Hazlett and Wu, 2011). Cellular innate control is the most important aspect of innate 
immunity allowing for the control and clearance of invading pathogens (Hazlett and Wu, 2011). Innate 
immune cells phagocytose microbes and eliminate them via enzymatic means or through the action of 
antimicrobial peptides (Hazlett and Wu, 2011). Phagocytes able to degrade pathogens can then present 
processed microbial peptide fragments on the surface of their cells for recognition by the adaptive immune 
system.  
Of particular importance in defence against M. tb is the action of circulating monocytes and tissue-
resident macrophages in the lung (alveolar macrophages) which generally are the first cells to interact with 
a pathogenic aerosol and have the ability to control infection in healthy individuals. It is hypothesised that 
in some individuals who are highly exposed to TB patients, the innate response at respiratory mucosa may 
be sufficient to prevent infection as indicated by long-term negative skin tests  (TST) (Modlin and Bloom, 
2013). It is possible that the vitamin D-dependent antimicrobial pathway may contribute to control in these 
high risk, yet healthy individuals (Figure 14). 
 
Figure 14: Vitamin-D antimicrobial pathway and hypothesised regulation of transcription of antimicrobial 






Macrophages and monocytes are phagocytic, large white blood cells which are important 
components of the innate immune response to M. tb (Liu et al., 2007, Maess et al., 2010). These phagocytes 
have the ability to engulf or phagocytose foreign particles and pathogens such as bacteria and mycobacteria 
(Maess et al., 2010). Once engulfed, the foreign body is sequestered in a membrane-bound vacuole called 
a phagosome (Aderem and Underhill, 1999). The phagosome fuses with a second membrane-bound 
organelle filled with degradative enzymes and other antimicrobial molecules, called a lysosome to form the 
phagolysosome (Aderem and Underhill, 1999). This joining results in the degradation of foreign particles, 
but is countered by of the ability of phagocytosed M. tb to inhibit phagolysosome fusion (Aderem and 
Underhill, 1999). Nonetheless, in vivo and ex vivo experiments have demonstrated the ability of 
macrophages and monocytes from healthy individuals to control M. tb infection (Demissie et al., 2004, 
Modlin and Bloom, 2013). This control of infection is thought to be at least partly mediated through the 
production of antimicrobial peptides for the destruction of internalised mycobacteria (Modlin and Bloom, 
2013, Agerberth et al., 2000).  
Mouse studies have shown that the main arm of antimicrobial clearance in murine macrophages is 
facilitated via nitric oxide synthase (Chan et al., 1995, MacMicking et al., 1997). Conversely, ex vivo human 
studies imply that the innate immune response during microbial challenge is mainly facilitated through the 
production of antimicrobial peptides rather than ROS-burst (Modlin and Bloom, 2013). This 
monocyte/macrophage antimycobacterial activity is partially mediated by Toll-like receptor (TLR2/1), 
vitamin D-dependent induction of potent antimicrobial peptides, cathelicidin and β-defensin 2 (DEFB4) 
(Modlin and Bloom, 2013, Campbell and Spector, 2012, Chun et al., 2015) (Figure 8). The Vitamin-D 
antimicrobial pathway (Summarized by Modlin and Bloom (2013) in Figure 14), involves the following 
key steps: (1) activation of TLR1/2 leads to the upregulation of CYP27b1 which converts 25-





activation of the vitamin D receptor resulting in (3) the production of CAMP and DEFB4 to mount an 
effective immune response (Modlin and Bloom, 2013, Adams et al., 2009). 
These antimicrobial peptides are in turn partially modulated by type II interferon, IFN-γ, which is 
mainly secreted by T-cells during bacterial infection (Modlin and Bloom, 2013).  Thus, effective immune 
control of M. tb, requires a robust T-helper type 1 (Th1) immune response, which has both a direct anti-TB 
effect but also influences the accompanying innate immune responses of macrophages and other antigen 
presenting cells (Montagnier, 2002, Teles et al., 2013). Indeed, current tuberculosis immunotherapy 
treatments and research are being aimed at the encouragement of Th1 responses to facilitate the efficient 
management of infection (Groschel et al., 2014). Both arms of the immune response are thus thought to act 
synergistically for effective control of mycobacterial infection.   
However, viral infection, especially HIV, is a known potent inducer of type I interferons such as 
IFN-α and IFN-β which may lead to downregulation of Type-I-interferon mediated T cell responses and 
downstream signalling pathways such as those that lead to potent induction of anti-microbial peptides in 
macrophages (Decker et al., 2005, Teles et al., 2013).  Furthermore, HIV-1 infection is associated with the 
induction of a cytokine storm in acute HIV-1 infection, with the elevated secretion of some cytokines, 
notably type I interferon, persisting through the chronic infection phase (Roberts et al., 2010, Stacey et al., 
2009). The impact of these cytokines or of HIV-1 proteins on anti-TB immunity has not been fully 
characterised and remains a key gap in knowledge in the field. 
1.7 Aim of Study 
Study of antimicrobial peptide expression in the face of type I/II interferon imbalance has the 
potential to lead to a more accurate understanding of the mechanisms underlying innate immune response 
dynamics in TB-HIV coinfection. Such knowledge may eventually facilitate better treatment for patients 





Firstly, to optimise RT-qPCR assays to quantitate levels of transcription of key components of the 
antimicrobial peptide pathway: CYP27b1, CYP24, Cathelicidin (CAMP), Beta-defensin (DEFB4), and 
Vitamin D receptor (VDR).   
Secondly, utilising primary CD14+ monocytes from healthy individuals, to assess the range of normal 
expression of these transcripts relative to the basal expression observed in the immortalised monocytic cell 
line, THP-1 cells. 
Thirdly, to assess the impact of recombinant human type I/II interferon on the production of the transcripts 
of interest in THP-1 cells and CD14+ healthy patient monocytes. 
1.8 Hypothesis 
We hypothesised that elevated levels of Type-I IFN (such as induced in viral infections like HIV-
1) result in decreased production of the Vitamin-D dependent antimicrobial peptides (Figure 15). 
Specifically, we hypothesise that exogenous application of Type-I IFN (at a physiologically relevant 
concentration to that seen in HIV infection) to innate phagocytes ex vivo will downregulate key 
antimicrobial peptides. If confirmed, this would provide a potential mechanism by which HIV-1 infection 






Figure 15: Illustrated Diagram of Hypothesis. Type II IFN (IFNγ) is upregulated during mycobacterial 
infection and facilitates the metabolism of vitamin D and upregulates the downstream expression of 
protective antimicrobial peptides. This protection is abrogated via the upregulation of Type I IFN (IFNα2a) 
during HIV infection.  
1.9 Rationale 
South Africa has one the highest prevalence of HIV infection in the world. People suffering from 
HIV are 30-40 times more likely to develop TB. Further, tuberculosis remains the greatest killer of HIV-
infected people worldwide. By gaining a better understanding of host defensive mechanisms, such as the 
vitamin D-dependent pathway, novel host-focused therapeutic treatments/vaccines may be designed to help 
the patient better control M. tb infection. Adjunctive immunotherapies have the potential to ameliorate the 
symptoms of TB or improve the speed of eliminating infection in conjunction with standard TB treatment.  
1.10 Specific Objectives 
The specific objectives of this study are as follows; 
Firstly, to optimise real-time PCR assays for CAMP, VDR, CYP24a1, CYP27b1, DEFB4 and GAPDH in 





Secondly, to compare the basal expression of CAMP, VDR, CYP24a1, CYP27b1, DEFB4 in THP-1 cells 
relative to CD14+ cells from healthy donors. 
Thirdly, to purify CD14+ cells (monocytes) from healthy donors to assess how gene expression of CAMP, 
VDR, CYP24a1, CYP27b1, DEFB4 is modulated by stimulation with recombinant human type I interferon 
(rhIFNα2a) and recombinant human type II interferon (rhIFNγ) in THP-1 cells and CD14+ human 
monocytes.  
2. CHAPTER TWO: Optimisation of qPCR Assays for Reliable Detection of Transcripts of 
Interest in the Vitamin-D Dependant Antimicrobial Pathway in the THP-1 Cell Line 
2.1 Brief Introduction 
Accurate detection of Vitamin-D dependent antimicrobial transcripts (CAMP and DEFB4) and 
associated regulatory genes (VDR, CYP24a1 and CYP27b1) requires an optimised and validated gene 
expression assay. Real-time PCR has been widely regarded as the gold standard for the quantification of 
genes since its establishment in the early 1980s. PCR has the benefit of being able to amplify low quantities 
of DNA (theoretically down to one copy) whilst avoiding the quantification of easy-to-degrade proteins 
which may affect assay accuracy. It also facilitates the ability to quantify many varying factors or genes at 
once. The success of this technology is a testament to its routine use in many different industries ranging 
from forensics to diagnostics. Even with the advent of modern transcriptomic technologies such as RNA 
sequencing (RNA-seq), qPCR remains a key technology for the validation of high throughput hypothesis 
generating technologies.  
2.1.1 Traditional PCR vs. Real-Time PCR 
Quantitative real-time polymerase chain reaction (qPCR) is an improvement on the traditional PCR 
first pioneered by Kary Mullis in 1983 (Kubista et al., 2006, Kozera and Rapacz, 2013). PCR utilises a pair 
of artificially created DNA oligonucleotides (called primers) which flank a target single-stranded DNA 





2006) and cycles of heat to dissociate double-stranded DNA and promote amplification. PCR generally has 
three phases; denaturation, annealing and elongation. The sample is heated to a particular temperature to 
facilitate the denaturation of double-stranded DNA to single-stranded DNA. The annealing step allows for 
the attachment of the primers to the single-stranded template. Finally, the elongation step entails the 
extension of the product via polymerase using the position of the primers to define the intended product 
(Kubista et al., 2006). This process is then repeated for a number of thermal cycles allowing for the 
exponential amplification of the targeted DNA sequence (Figure 16) (Kubista et al., 2006). The reaction 
eventually plateaus when the reagents in the reaction are used up (Kubista et al., 2006). A 100% efficient 
PCR reaction will result in the exponential doubling of product with every cycle. 
As with conventional PCR, qPCR also involves the exponential replication of small samples of DNA 
utilising primers, dNTPs and Taq polymerase. However, via the use of intercalating dyes (such as SYBR 
green I) or hybridization probes (TaqMan®), cycles of amplification of targeted DNA can be measured in 
real time (following each thermal cycle) via the measurement of fluorescent signal as a measure of the 
exponential amplification of the target sequence (Figure 17) (Kubista et al., 2006, Heid et al., 1996). This 
allows for the quantification of gene expression levels under particular conditions.  The amplified product 
can also be run on an agarose gel after the qPCR has been concluded, allowing for validation, sequencing, 
cloning and possible transformation.
 






Figure 17: Generalised Schematic of Real-Time Polymerase Chain Reaction using Intercalating DNA Dye 
(SYBR Green) to Detect the Amplification of cDNA. 
2.1.2 Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
Guidelines 
Since the advent of real-time quantitative PCR, many studies have used this technology as a 
platform for discovery. It has been extensively used in almost all aspects of biology from agriculture to 
clinical diagnostics. This is reflected in the numerous publications which have presented qPCR data, with 
most studies using varying amplification conditions, differing kits, primers, chemistries, and varying 
methods of nucleic acid extraction. As such, there has been a lack of consensus on how to optimally run 
and analyse qPCR experiments and data. This had an adverse effect on assay reproducibility and 
transparency. (Bustin et al., 2009). To remedy this, the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments, or MIQE guidelines, were published by Stephen Bustin et al. in 
2009. The paper’s objective was to provide a general set of guidelines or minimum criteria to which all 
studies utilising qPCR should adhere to promote transparency and reproducibility (Figure 18). These 
guidelines have now become the standard for all studies utilising real-time PCR. Many biotech companies 





experimental data to the guidelines easier.  These guidelines were followed in the optimisation of the qPCR 










Figure 18: Checklist of Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(Bustin et al., 2009) 
2.1.3 Optimisation of Issues Encountered in Real-Time PCR 
There are several experimental obstacles that need to be optimised for a successful qPCR protocol 
to be established; 
2.1.3.1 Primer-Dimer 
Primer-dimer refers to the preferential binding of the forward and reverse primers to one another 
rather than the intended target sequence. This occurs due to the high occurrence of complementary 
nucleotide bases between the primers leading to hybridization to form a double-stranded product. This 
unintended by-product of a poorly optimised PCR protocol will result in the competitive usage of reaction 
reagents, thus decreasing the ability of the reaction to efficiently amplify the target DNA sequence. If 
present, primer-dimers can decrease the efficiency of a given PCR reaction, thus skewing the results for 
accurate quantitative analysis of the transcript of interest. Primer-dimers generally range from about thirty 
to fifty nucleotide bases in length and are identified by a melting peak at a lower temperature to that of the 
target amplicon. In an optimised qPCR protocol, the elimination of primer-dimer is an essential step 
(Raymaekers et al., 2009). 
2.1.3.2 Non-Specific Amplification 
  Non-specific implication refers to the off-target amplification of an unintentional product during a 
PCR. This occurs when the PCR primers are complementary to other unintended regions on the template 
DNA, thus resulting in one or more products being amplified in addition to the target of interest. Non-
specific amplification can be a result of two main causes. First, poorly designed primers can result in 
unintended amplification or primer dimer. Online bioinformatics tools such as NCBI’s Primer-BLAST have 
been developed to allow assessment of the binding characteristics of a theoretical primer before it is 
manufactured, saving time and money. Secondly, non-specific amplification in gene expression 





contamination often occurs when manoeuvres to remove genomic DNA from extracted RNA (such as 
DNase treatment or DNA binding) are inefficient. 
2.1.3.3 Reference Gene Validation  
Relative quantification of gene expression profiles using real-time PCR requires the use of robust 
endogenous reference genes for the adequate normalisation of qPCR data (Kozera and Rapacz, 2013). A 
reference gene is a particular gene whose expression remains constant independent of stimulation or 
activation, genes fulfilling "housekeeping" functions are often the best candidates. An ideal reference gene 
allows for the normalisation of gene expression data to cell number (Kozera and Rapacz, 2013). In a fully 
optimised relative qPCR protocol, the reference gene should be stably expressed regardless of experimental 
treatment for a specific number of cells. Some reference genes, however, may be modulated by 
experimental stimulations or tissue and will influence the accuracy of the quantification of gene expression. 
As such, it is essential to validate several potential reference genes to assure that they are stably expressed 
in the cell type being used in the experiment. 
2.1.3.4 Differential Expression between Cell Types 
Expression of a transcript can be modulated by many different factors such as media type, cell type, 
the state of activation, culture conditions and others factors. Consideration must be given to the cell type 
used for optimisation of qPCR assays, particularly in the use of cell lines. Certain transcripts may be 
overexpressed in immortalised cell lines, whilst in others, they may be underexpressed or lacking altogether.  
2.1.3.5 RNA Quality 
The accuracy of gene expression assays is critically influenced by the quantity and quality of the 
RNA extracted prior to real-time PCR (Fleige and Pfaffl, 2006). The quantification and integrity assessment 
of extracted RNA is an essential practice to ensure the accuracy and reproducibility of a qPCR-based 
experiment or any other RNA-based analysis such as RNA-seq (Fleige and Pfaffl, 2006). Low-quality RNA 





Several steps should be taken prior to downstream analyses to ensure that the RNA is of sufficiently 
quality for accurate qPCR assays. Purified RNA should adhere to several criteria. Firstly, the RNA 
preparation should be free from contaminating cellular artefacts such as genomic DNA and proteins. Total 
RNA should also be free of reagents which were used in the initial isolation such as ethanol or guanidine 
thiocyanate which can inhibit reverse transcriptase or downstream qPCR. The most important aspect for 
the extraction of high-quality RNA is to avoid RNase contamination. Contamination will result in the 
degradation of RNA and loss of ability to accurately assess sensitive gene expression profiles. RNase 
contamination also hampers the ability of the RNA to be stored long term. Fortunately, commercially 
available RNase inhibitors are available for the efficient removal of RNases from lab surfaces and pipettes. 
The use RNase-free tubes, pipette tips, and other consumable reagents is an essential step for any RNA 
work. 
Analysis and quantification of total RNA can be done in one of three ways. Traditionally, the gold 
standard for the detection of RNA quality was to run extracted RNA on a 3-(N-morpholino) propanesulfonic 
acid (MOPS) gel via electrophoresis. Visualisation of two distinct bands, 28S (±4,600 bases) and 18S 
(±1,800 bases) with limited smearing, is indicative of high-quality RNA. This has been improved upon 
using modern microfluidic technology in instruments such as Agilent’s Bioanalyzer which allows for the 
assessment of both the quantity of RNA and its associated quality via an RNA integrity number (RIN) from 
1-10 (where 10 is RNA of the highest quality). For qPCR and RNA-Seq, RIN values should always be 
greater than 7. A less accurate, but faster method of RNA integrity assessment is via spectrophotometry. 
NanoDrop technology allows for the assessment of RNA quality and quantity via this method. Quality is 
assessed as a ratio of absorbance at 260 nm and 280 nm, or 230 nm. High quality, contaminate-free RNA 





2.2 Methods and Materials 
2.2.1 Cells and Reagents 
2.2.1.1 THP-1 Cells 
2.2.1.1.1 Background of THP-1 Cell Line 
THP-1 cells are a monocytic cell line acquired from a one-year-old infant suffering from acute 
monocytic leukaemia and are available commercially from the American Type Culture Collection (ATCC) 
(ATCC, 2015). Cells reside in suspension and are phagocytic whilst lacking surface and cytoplasmic IgG 
(Chanput et al., 2014). In the undifferentiated state, THP-1 cells are weakly stimulated via the application 
of toll-like receptor agonists, however, this situation changes upon their activation to macrophages 
(Chanput et al., 2014). Such differentiation is achieved via the application of phorbol 12-myristate 12 
acetate (PMA) (Park et al., 2007). Application of PMA for cellular activation is terminal (irreversible), 
meaning that THP-1 cells will no longer undergo mitosis and will adhere and metabolise more slowly in a 
manner characteristic to macrophages (Chanput et al., 2014).  For this study, THP-1 cells were evaluated 
as monocytes. 
2.2.1.1.2 Maintenance of Cell Culture 
THP-1 cells were acquired (ATCC) and maintained in ATCC formulated RPMI-1640 medium 
supplemented with 2-mercaptoethanol (0.5 mM) (Sigma-Aldrich), fetal bovine serum (10%) (Merck), Non-
Essential Amino Acids (NEAA) (1%) (Gibco®), HEPES (10%), L-glutamine (10%) (Lonza) and sodium 
pyruvate (1%) (Gibco®). The cells were incubated horizontally in a 5% CO2 environment at 37° C and 
maintained at a cell concentration of ±1.0 x 106 cells/ml. Media was substituted correcting for the right cell 
concentration every 3 days. The cells were expanded until an adequately high number was generated at 
which time they were frozen down at a concentration of 5x106 cells/mL and stored in liquid nitrogen as per 
2.2.1.1.3 below. To control for potential additive deleterious effects which may arise due to the long culture 
of THP-1 cells in vitro, all THP-1 cells required for downstream optimisation and stimulation experiments 





2.2.1.1.3 Freezing & Cryopreservation 
Freezing of THP-1 cells was implemented in accordance with the protocol set out by the ATCC. 
Briefly, THP-1 cells were spun down at 15000 rpm for 10 min, resuspended in freezing medium consisting 
of 40% standard culture media (see 2.1.1.2 above), 10 % dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and 
50 % fetal bovine serum (FBS). Cells were then placed in a 2 ml cryogenic vial (Corning). Cryovials were 
consigned to a stratacooler (Agilent Technologies) and placed in a -80° C freezer overnight. The following 
day, cryovials were immediately transferred to gas-phase liquid nitrogen storage.  
2.2.1.1.4 Thawing of THP-1 cells 
Thawing of THP-1 cells was done in accordance with the protocol set out by the ATCC.  Frozen 
THP-1 cells were retrieved from gas-phase liquid nitrogen storage and transferred to a 37° C water bath 
and agitated gently. Samples were thawed rapidly until a single ice chip remained at which point the 
cryovial was decontaminated using 70% ethanol. Samples were then transferred drop-wise into 9 ml of 
complete culture media (see 2.1.1.2) and spun down at 1500 rpm for 7 min. The pellet was resuspended in 
complete culture medium and incubated in accordance with the details mentioned in 2.1.1.2 above. 
2.2.2 RNA Isolation and cDNA Synthesis 
2.2.2.1 Principle of Methods  
Any investigation into gene expression is fundamentally based on an understanding of the central 
dogma of biology. The principle underlying the dogma: transcription of a nucleic acid sequence information 
(gDNA -> mRNA) and the subsequent translation of that sequence into a protein (mRNA -> protein). The 
process involves three major biopolymers: DNA, RNA and proteins. DNA is unwound by an enzyme (DNA 
helicase) that then allows for RNA polymerase to start transcribing a strand of the messenger, or mRNA 
from the DNA template. Once transcribed the non-coding introns of the mRNA are then spliced out of the 
mRNA strand, leaving an mRNA composed of exons alone. This is called post-transcriptional modification, 





acids to form proteins. These proteins then undergo conformation change in a process termed post-
translational modification to form mature proteins.  
During gene expression analyses nucleated cells are activated or have some treatment imposed on them for 
a certain period, after which the cells are then lysed/homogenised. The mRNA present represents gene 
expression and may have a non-linear relationship to levels of proteins (which can be studied using 
proteomics). RNA is then isolated, purified and quantified. Complementary DNA (cDNA) refers to the 
single strand of DNA which is artificially transcribed and amplified from the mRNA utilising primers, 
reverse transcriptase (RT) and deoxyribonucleotide triphosphate (dNTPs). Such amplification is achieved 
using varying thermal cycles which facilitate the binding of primers, the activity of reverse transcriptase 
and melting of the cDNA from the mRNA template. The synthesis of cDNA continues until all reaction 
reagents are used up at which point the concentration of cDNA plateaus out. The cDNA can then be 
analysed via PCR and qPCR using gene specific primers to assess relative gene expression. 
2.2.2.2 RNA Isolation, QC and Reverse Transcription Procedure 
For all isolations, cells (>1x106 cells/ml) were pelleted and resuspended in Buffer RLT Plus and 
homogenised (Qiagen, RNeasy® Plus Mini Kit cat. No. 74104).  RNA lysates were transferred to gDNA 
Eliminator spin column and centrifuged at 9000 x g for 30 sec.  The supernatant was removed to a new 
RNeasy spin column and centrifuged at 9000 x g for 15 sec. Flow through was then discarded. RW1 buffer 
was added and the tube was spun again at 9000 x g for 15 sec. Flow through was then discarded.  RPE 
buffer was added and the tube was spun again at 9000 x g for 15 sec. Flow through was then discarded. 
RPE buffer was added and the tube was spun again at 9000 x g for 2 min. RNase-free water was added to 
the spin column and spun at 9000 x g rpm for 1 min to elute RNA. Eluted RNA was then quantified via 
Nanodrop. The cDNA templates were reverse transcribed from isolated RNA using iScript™ cDNA 
Synthesis Kit (BioRad, cat. No. 1708891). RNA and cDNA concentration was then analysed via Nanodrop 





2.2.3 Primers and Real Time PCR 
The PCR primers used for cathelicidin (CAMP), cytochrome P450C24 (CYP24a1), cytochrome 
P450 family 27 subfamily B member 1 (CYP27b1), β-Defensin 2 (DEFB4) and vitamin D receptor (VDR) 
real-time quantitative PCR were validated in our laboratory using NCBI Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) (see Appendix 2 and 3) and Primer 3 Plus 
(http://primer3plus.com/cgi-bin/dev/primer3plus.cgi) to ensure that all primers fulfilled the criteria required 
for an optimal primer for each qPCR target gene (see Appendix 1 and discussion in 2.3.1). Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), ubiquitin C (UBC) and β-actin (ACTB) were utilised as reference 
genes for normalisation of data. Amplified product for each set of primers was subjected to standard PCR 
and run on a 2.5% agarose gel to determine whether the desired product was being amplified as well as to 
optimise the PCR conditions (annealing temperature and extension time) before moving on to real-time 
PCR optimisation. 
The qPCR assays for CAMP, CYP24a1, CYP27b1, DEFB4, VDR, UBC, GAPDH and ACTB were 
performed on a LightCycler® 480 Real-Time PCR System (Roche).  Each PCR reaction comprised of 
0.0625 – 0.25 pmol/μL of each primer, 5 μL SYBR Green I Master mix (2X) (Roche), 1 μL cDNA and 
water to 10 μL.  Reactions were run in duplicate on a Roche LightCycler® 480 version 1.5 with one cycle 
at 95 ˚C (10 min), followed by 45 cycles consisting of denaturation at 95°C for 30 seconds, annealing at 
60°C for 30 seconds and elongation at 72° for 30 seconds.  Detection of the fluorescent products was carried 
out at the end of the 72 ˚C extension period. To confirm amplification specificity, the PCR products were 
subjected to a melting curve analysis and 2.5% agarose gel electrophoresis.  Serial dilutions of cDNA from 
total RNA were performed for each target gene. These served as standard curves for quantitative analysis. 
Controls without any added RNA (No template controls) were tested and demonstrated the absence of 





Table 1: Final Optimized Primers Sequences and Associated Information 
Gene 
Code 






(5’ – 3’) 
Reverse Primer 
(5’ – 3’) 
CAMP NM_004345.4 59 0.250 CCAGGACGACACAGCAGTCA CTTCACCAGCCCGTCCTTC 
VDR NM_000376.2 135 0.250 AGGCTGCAAAGGCTTCTTC ATGTCCACACAGCGTTTGAG 
CYP24a1 NM_000782.4 61 0.250 CGCAGCGGCTGGAGAT CCGTAGCCTTCTTTGCGGTA 
CYP27b1 NM_000785 233 0.250 TCCATCCTGGGAAATGTGACA ACAGGGTACAGTCTTAGCACTT 
DEFB4 NM_004942.3 75 0.250 GGTGTTTTTGGTGGTATAGGCG AGGGCAAAAGACTGGATGACA 
GAPDH NM_002046.5 225 0.0625 AAGGTCGGAGTCAACGGATT CTCCTGGAAGATGGTGATGG 
UBC NM_021009.6 202 0.50 TTTCCAGAGAGCGGAACAG TCACGAAGATCTGCATTGTCAAG 
ACTB NM_001101.3 121 0.50 GATCAAGATCATTGCTCCTCCTG GCCGGACTCGTCATACTCC 
 
2.3 Results 
Each gene was taken through all optimisation steps explained above. In order to avoid repetition, 
the following section will focus on the troubleshooting of the problems that occurred during qPCR assay 
design and optimisation and a discussion of the lessons learned and issues addressed in each area of 
optimisation. 
2.3.1 Bioinformatic Validation of Primers 
A literature search of published qPCR-based research was conducted to acquire published primer 
pairs for the transcripts of interest. Optimal primers were then shortlisted to satisfy a number of conditions. 
They should be approximately 19-25 base pairs in length and amplify a product no bigger than 400 base 
pairs to ensure similar melting temperatures and specific amplification of product. Longer amplicons 
(>400bp) have a tendency toward forming nonspecific secondary peaks that hamper the accuracy of the 
assay. They should be designed to reduce the chance of secondary structure (hairpins, self-dimer etc.) 
formation as these structures may inhibit the binding of the primers to the target sequence or result in no 
specific peaks. The GC content of each primer should be in the range of 20-70 % and each member of the 
pair should have similar melting temperatures to ensure efficient binding and dissociation of the primers to 
the target cDNA sequence. For gene expression, it is important that the primers should account for all 
known isoforms or variants of the target sequence. Exon-exon spanning primers are desirable to reduce the 






Each primer pair identified from the literature was assessed using NCBI’s Primer-BLAST to ensure 
that a) the primers were detected by the database and b) the primers were exon-exon boundary spanning 
(see Appendix 2). The primer pair was then BLASTed against the human genome to assess the specificity 
of the primer to a specific transcript (Figure 19). Among those identified in the literature, primer pairs for 
each transcript of interest were selected for further consideration based on their specificity and as well as 










Figure 19: Bioinformatic Validation of Primers for Vitamin D Receptor using NCBI’s Primer-BLAST. 
The online analysis allows for the detection of potential off-target amplicons, primer binding regions, 
specificity and GC content of both sense and antisense primer. 
Prospective primer pairs were then assessed using the Primer 3 Plus online tool (Figure 20) to 
calculate the probability of secondary structure formation between the given primers, the GC content and 
3’ end stability.  
 
Figure 20: Primer 3 Plus Analysis for Secondary Structures, GC Content and 3’ Stability for Vitamin D 
Receptor (Bottom Right) and an Example of an Inappropriate Primer Pair (Top Right) 
Primer sequences which failed to pass both of the online analyses were discarded, whilst primers 
which passed were ordered, synthesised and tested in-house. All primer pairs listed in Table 1 were tested 
and found to satisfy all the bioinformatic requirements for an optimal primer. Having been bioinformatically 





2.3.1 Validation of Genes of Interest by Agarose Gel Electrophoresis 
To further validate the specificity of the primer sets designed for CAMP, VDR, CYP24a1, 
CYP27b1 and DEFB4, the amplified PCR products were subjected to 2.5% agarose gel stained with SYBR 
Safe. Each product demonstrated a single amplicon (Figure 21).  The amplified PCR product sizes were all 
in agreement with the bioinformatically predicted values (see Table 1). 
 
Figure 21: Gel Validation of Amplified Genes of Interest Product Size via Gel Electrophoresis. The size 
of each band correlated well with the predicted product length. 
2.3.2 Optimisation of qPCR Conditions to Remove Primer-Dimer 
Initial experiments with a newly designed primer pair were conducted using the primers at a final 
concentration of 0.50 pM.  When real-time experiment PCR melt curves showed the presence of primer-
dimers (secondary peak which melts at a lower temperature relative to the specific peak or a peak present 
in the no template control), the final primer concentration in the reaction was diluted two-fold until the 
primer-dimer was no longer visible on the melt curve analysis. Figure 22 illustrates this for the GAPDH 





sequentially reduced until the secondary peak at 76-78°C (indicative of primer-dimer in both the sample 
and no template control) was completely eliminated at a concentration of 0.0625 pM.   
 
Figure 22: Elimination of Primer-Dimer in for the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
qPCR via serial dilution of Primers. 
2.3.3 Optimisation of qPCR Conditions to Remove Non-Specific Amplification 
2.3.3.1 Genomic DNA Contamination of template cDNA 
Non-specific amplification is the undesirable amplification of an unintended secondary product 





Primers were designed such that only specific amplicons would be amplified in the absence of 
contaminating DNA. In the presence of genomic DNA contamination, the exon-exon spanning design of 
the primers allowed for its easy detection since the unintentional product (intron-containing) was longer 
and melted at a higher temperature relative to that of the intended product.  
This optimisation is illustrated for the CAMP gene.  Melt curve analysis was carried out after real-
time PCR of CAMP from THP-1 samples. The specific product melted at approximately 81° C and a 
secondary peak was observed to melt at approximately 87° (Figure 24B). The no template control (NTC) 
was devoid of any amplification, implying that the secondary peak was likely the result of genomic DNA 
contamination of the template cDNA rather than primer dimer or DNA contamination. To test this idea, 
isolated RNA, stored from the same experiment had been at -80° C was re-concentrated via ethanol 
precipitation and subjected to additional DNase treatment.    
 






Figure 24: Melt Curve Analyses of CAMP showing A) the Melting Curves and B) the Associated Melting 
Peaks. Non-specific amplification as a result of genomic DNA contamination can be observed at a melting 
temperature of approximately 86°C. 
After the additional DNase treatment, the samples were reverse transcribed and used for real-time 
PCR. The resulting melt curve analysis showed that the additional DNase treatment completely eliminated 
the secondary product (Figure 26B). The primer pairs specific for CAMP were found to be particularly 
sensitive to any gDNA contamination. 
 






Figure 26: Melt Curve Analyses of CAMP showing A) the Melting Curve and B) the Associated Melting 
Peaks Post Additional DNase Treatment showing a single specific product being amplified. 
Genomic DNA contamination of total RNA also interfered with the ability of the NanoDrop to 
accurately quantify RNA post-nucleic acid extraction. As such, this skewed the reaction concentration of 
DNase used during the removal of DNA from the total RNA preparation. A higher reaction volume of 1.5 
times the recommended volume of DNase was used per sample to overcome this particular issue and was 
successfully used in all RNA extractions going forward. 
2.3.4 Assessment of RNA Quality 
The quality of the purified, DNase treated RNA was assessed for use in downstream real-time PCR 
applications using the Agilent 2100 Bioanalyser. The quality of the RNA used in any gene expression assay 
is the single most important aspect of the assay. Poor quality RNA can affect the point at which a real-time 
PCR machine can detect signal by significantly delaying amplification. If the objective of the assay is to 
look for a low copy transcripts RNA quality becomes even more important as these sensitive transcripts 
may be lost due to damaged RNA. An RNA integrity number (RIN) value of 7 or above is adequate for 
real-time applications.  
Purified, DNase-treated RNA from lysed THP-1 cells yielded a RIN value of 8 indicating high-





downstream qPCR (Figure 27). A high-quality RNA is illustrated by two peaks at 2000 and 4000 
nucleotides. 
 
Figure 27: Output from Agilent Bioanalyser 2100 Showing High-Quality RNA (RIN=8) Extracted using 
the RNeasy Plus Mini Kit in Conjunction with an Additional DNase Treatment. 
2.3.5 Formation of Standard Curves for Relative Analyses 
Complementary DNA (cDNA) synthesised from 1 µg of RNA was serially diluted and subjected 
to qPCR to create an individual standard curve for each gene of interest. The primary objective of this 
was to determine the efficiency of the qPCR assay per gene which is required to accurately quantify gene 
expression relative to the reference gene (GAPDH) using the Pfaffl equation (Pfaffl, 2001); 
 
𝑹 =
𝑬𝒇𝒇𝒄𝒊𝒆𝒏𝒄𝒚(𝒕𝒂𝒓𝒈𝒆𝒕)𝑪𝒕(𝑻𝒂𝒓𝒈𝒆𝒕,   𝑼𝒏𝒕𝒓𝒆𝒂𝒕𝒆𝒅)−𝑪𝒕(𝑻𝒂𝒓𝒈𝒆𝒕,   𝑻𝒓𝒆𝒂𝒕𝒆𝒅)







The Pfaffl equation is used in instances where the qPCR reaction efficiencies between the gene of interest 
and the reference gene are not similar or equal to 2 (100% efficient). For all genes of interest, the reaction 
efficiencies were optimised to be greater or equal to 85% and have an error less than 0.2 (Table 2.). 
Table 2: Summary of Optimized Standard Curves for All Genes of Interest 
Gene Code Efficiency 
(%) 
Slope Error 
CAMP 92 -3.521 0.0428 
VDR 89 -3.614 0.00427 
CYP24a1 92 -3.534 0.00415 
CYP27b1 95 -3.443 0.00609 
DEFB4 94 -3.475 0.106 
GAPDH 86 -3.704 0.0228 
UBC 92 -3.528 0.0370 
ACTB 94 -3.487 0.276 
 
2.3.6 Lack of Reliable Expression of DEFB4 in THP-1 Cells 
Beta-defensin 2 (DEFB4) primers were bioinformatically validated using primer-BLAST. 
However, qPCR analysis of DEFB4 in THP-1 cell line revealed no difference between the no template 
control and cDNA synthesised from THP-1 cells (Figure 28 A-C). Complementary DNA synthesised from 
a reference RNA library (Human Reference RNA, Agilent), composed of 10 differing human tissues, was 
utilised to test the DEFB4-specific primers under the standard optimised qPCR cycling conditions. In 
contrast to the THP-1 cell line, the specific product was amplified and detected from the reference cDNA 
libraries synthesises from comparable total RNA (Figure 28 D-F). Like DEFB4, CYP24a1 also was also 
undetectable in THP-1 cells - but was reproducibly detectable within the reference cDNA library (Data not 
shown). Further, specific amplification of both transcripts was again reproducibly observed in patient 
samples during stimulation experiments (see Chapter 3). 
From this, we concluded that the THP-1 cells which were purchased from the ATCC and utilised 
for the in vitro optimisation of these qPCR assays were either lacking DEFB4 and CYP24a1 or the 






Figure 28: Detection of DEFB4 in THP-1 Cells vs. a Reference cDNA Library. A) Amplification curves 
of DEFB4 in THP-1 cells. B) Melting Curves of DEFB4 in THP-1 cells. C) Melting peaks of DEFB4 in 
THP-1 cells. D) Amplification curves of DEFB4 in a reference cDNA library. E) Melting Curves of DEFB4 





2.3.7 Validation of Reference Genes 
The accuracy of relative gene expression experiments using real-time PCR is highly reliant on the 
simultaneous measurement of a stably expressed endogenous control gene that is not affected by an 
experimental treatment. Measurement of such a gene allows any variation observed between treatments to 
be analysed after normalisation to cell number.  Although certain "housekeeping" genes are generally 
selected for use as a reference, it is best practice to experimentally determine whether expression of a 
selected reference gene is stable under the experimental conditions specific to a set of experiments.  
To test the stability of expression under stimulation conditions, we tested three potential reference 
genes (Figure 29). Primers for hypoxanthine-guanine phosphoribosyltransferase (HPRT), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and 18S were optimised (Figure 28). THP-1 cells (2 x 106) were 
stimulated with recombinant cytokines (IFN-γ or IL-10) or were left unstimulated. After cell lysis, 0.5 µg 
total RNA from each condition was reverse transcribed and used for qPCR analysis. For each of the three 
genes, there was relatively little variation in the expression of each gene across the three conditions.  
Interestingly, the pattern of slight variation observed across conditions was common to all three reference 
gene candidates which we concluded meant that differences in cell number between conditions, rather than 
condition-specific induction of each of the transcripts, accounted for the differences. Despite efforts to keep 
cell numbers between the experimental conditions equivalent for this experiment, this artefact could have 
occurred during cell culture, nucleic acid extraction/purification, or reverse transcription of mRNA to 
cDNA. As all three potential reference genes behaved equivalently and showed no evidence of modulation 
by the cytokine stimulations, we decided to move forward with GAPDH as an appropriate reference gene 






Figure 29: Reference Gene Validation Experiment. HPRT, GAPDH and 18S all found to be suitable 
reference gene candidates for downstream relative qPCR gene expression assays. 
2.4 Discussion and Conclusion 
Even in the face of newer technologies such as RNA-seq real-time PCR remains the gold standard 
for gene expression assays in molecular studies. In this study, real-time PCR assays for the reliable and 
reproducible detection of CAMP, VDR, CYP24a1, CYP27b1 and DEFB4 were optimised for relative 
analysis using the Light Cycler 480. SYBR Green was selected over hybridization probes as the chosen 
method of quantitative chemistry for this thesis due to its ease of design, economical attributes, simple 
validation of amplified product (via melt curves) as well as the ability to better optimise a real-time PCR 
reaction per individual genes. However, the trade-off of this detection chemistry is the inability to design 
multiplex experiments. 
Primers were bioinformatically validated in silico and tested for the THP-1 cell line to test for 
reliable reproducibility of gene expression. All genes were optimised to work under the following qPCR 
conditions; pre-amplification for 7 minutes at 95° C, followed by 45 cycles of denaturation at 95° C for 30 
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seconds. All amplified transcript product sizes were confirmed via gel electrophoresis and found to be the 
expected size. 
Detectable, accurate standard curves which adhere to the MIQE guidelines were constructed for 
CAMP, VDR, and CYP27b1 using the THP-1 cell line.   In contrast, such standard curves could not be 
constructed for CYP24a1 and DEFB4 using the THP-1 cell line. In contrast to previously published studies, 
THP-1 cells cultured in vitro in our laboratory seemed to express low levels of these transcripts that were 
below the limit of detection even at high cell numbers (Adams et al., 2009, Gottfried et al., 2006, Heulens 
et al., 2016). However, as will be presented in Chapter 3, DEFB4 and CYP24a1 were accurately detected 
in human monocytes, alveolar macrophages and bulk PBMCs suggesting that the "problem" for these two 
transcripts was specific to THP-1 cells. In order to overcome this problem, real-time PCR assays for both 
of these genes were optimised using pooled reference mRNA which was reverse transcribed to cDNA. The 
lack, or minimal expression, of these transcripts in THP-1 cells, may be due to several potential factors. 
Firstly, the culture of THP-1 cells in vitamin D-deficient media may have had an inhibitory effect on the 
ability of these monocytic cells to transcribe mRNA relevant to this particular pathway, this will be fully 
discussed in Chapter 3 of this manuscript. Alternatively, the immortalised nature of the cell line may have 
contributed to this phenomenon. It is possible for cells which are constantly dividing for a long period to 
acquire mutations or short nucleotide polymorphisms which may modulate the cells ability to express 
particular transcripts. Lastly, the expression of these particular transcripts may only be facilitated through 
the adequate activation of the pathway via an appropriate TLR-agonist association. A potential limitation 
of this assay is the phenomenon of transcriptional data not necessarily correlating with protein data (Gry et 
al., 2009). Although this is beyond the scope of this study, the next step would be to conduct quantitative 
protein assays such as Luminex, ELISA or Western blot for the validation of transcriptomic data and 
facilitation of stronger conclusions. 
In conclusion, the real-time PCR assays for the detection of antimicrobial peptides and upstream 





of questions for future in vitro and ex vivo studies in our laboratory. Using the methodology described in 
this chapter, additional qPCR assays can be developed to validate novel genes of interest which may be 
identified using unbiased hypothesis-generating technologies such as RNA-seq. I found that efficient 
elimination of genomic DNA was achieved using a gDNA elimination column (Qiagen) in conjunction 
with an additional DNase treatment provided high quality (RIN=8) RNA that was appropriate for use in 
downstream qPCR assays. Interestingly, I found that that CYP24a1 and DEFB4 expression in unstimulated 
THP-1 cells was either inhibited or lacking entirely.  In the data presented here, I have optimised a one-
plate real-time PCR assay for the accurate and reliable detection of CAMP, VDR, CYP24a1, CYP27b1 and 
DEFB4; this work provided the methodological background for the experiments presented in Chapter 3 and 
will facilitate future experiments that require the relative quantification of these transcripts during 
bacterial/viral infection of innate immune  cells.
3 CHAPTER THREE: Effect of Type I/II Interferon Stimulation on the Expression of 
Transcripts of Interest in Healthy Patient CD14+ Cells and the THP-1 Monocytic Cell 
Line 
3.1 Brief Introduction 
Cell lines have been successfully used as biologically relevant proxies of primary human 
cells/tissues in medical research for many years. They provide a platform for the study of human cells 
without the ethical and practical constraints that restrict the acquisition and use of primary cells/tissues from 
human donors (Chanput et al., 2014). There is, however, a debate around the appropriate use of cell lines 
vs. primary cells for the optimisation of assays for the investigation of specific biological questions that 
have clinical implications. Certainly, results that have been achieved in cell lines should be validated in 
primary human tissues.  The THP-1 is a monocytic cell line acquired from a one-year-old male infant 
suffering from acute monocytic leukaemia which was first characterised in 1980 (Chanput et al., 2014, 





system for elucidating monocytic and macrophage biochemical pathways, bacterial infection/phagocytosis 
assays, signalling pathways and the transport of nutrients, proteins and drugs (Chanput et al., 2014).  
The use of THP-1 cells has several advantages; Firstly, THP-1 cells allow for greater 
reproducibility between multiple experiments due to their homogenous phenotype and genotype, thus 
reducing variation commonly observed from patient-to-patient when using primary cells.  Secondly, they 
recover well from cryopreservation and can remain in culture for up to three months (passage 25) without 
deleterious changes in cell activity or loss of sensitivity to an antigen or drug (Chanput et al., 2014).  The 
cells have been reported to double every 35-50 hours making them readily available for research purposes 
in a short duration of time. Conversely, the acquisition of buffy coats for large scale primary monocyte 
work is more time intensive or limited in many research settings.  
THP-1 cells’ ease of use is, however, offset by some inherent limitations. In vitro differentiation of THP-1 
cells to a more macrophage-like state facilitates the over-expression of certain genes; the induction of this 
transcriptional program is thought to perhaps mask the subtle, though significant, effects of certain 
stimulants, ligands and agonists. (Schildberger et al., 2013, Bruckmeier et al., 2012, Hijiya et al., 2002, 
Park et al., 2007). The in vitro culture of THP-1 cells under controlled conditions (relative to their natural 
environment within the host) is also hypothesised to have an effect on the phenotype and gene expression 
profile of THP-1 cells, due to lack of adequate cell signalling molecules or media deficient in some 
endogenous compounds required for “normal” functioning and expression (Schildberger et al., 2013).  
THP-1 cells remain a valuable and informative biological system for the study of monocytes and 
macrophages, however, key differences in their inherent cancerous biology and the consequence of constant 
in vitro culture make the relationships between primary monocytes and THP-1 cells one of resemblance 
rather than a system that perfectly mimics the physiological reality. Notable differences between THP-1 
cells and primary monocytes have been reported in studies that measured basal gene expression and 





study is the effect of type I/II interferon on the basal expression of key genes within THP-1 cells and CD14+ 
healthy patient monocytes. 
As discussed in detail above, the interferon response protects against microbial invasion and has 
been shown to both directly inhibit the growth of viruses and bacteria as well as play a significant role in 
the priming of the immune system for a protective response. Almost 60 years ago, interferon was first 
discovered as a secreted factor from virally infected cells which elicited a protective response in the 
immediate cellular environment by preventing subsequent infection (Isaacs and Lindenmann, 1957). The 
large group of secreted factors was termed interferons due to their ubiquitous ability to stimulate the 
transcription and upregulation of antiviral and antibacterial gene motifs which in turn facilitated host 
protection (Decker et al., 2005). In mouse knockout studies, animals with an IFN deficient phenotype were 
highly susceptible to microbial challenge and displayed increased mortality (Schroder et al., 2004, Huang 
et al., 1993). The classification of two interferon types, type I and II, is based on the cell surface receptors 
to which they preferentially bind. Type I IFN bind to the IFN alpha receptor (IFNAR), which consists of 
two subunits; IFNAR1 and IFNAR2. Type II IFN binds to the IFNγ receptor (IFNGR) which is composed 
of two chains; IFNGR1 and IFNGR2 (Sivro et al., 2014). Both receptors modulate antimicrobial gene 
expression via the JAK-STAT signalling pathway (Decker et al., 2005). Both types also regulate the 
differentiation of T-helper cells impacting T-cell immunity in addition to the innate immune responses 
(Decker et al., 2005). 
Type I IFNs, of which there are 20, are predominantly involved in the antiviral response during 
viral infection of the host (Decker et al., 2005). In mammals, IFN-α, IFN-β, IFN-ϖ, IFN-ĸ and IFN-Ɛ are 
the predominant type I IFN genes (Decker et al., 2005). Conversely, the type II IFN family consists of only 
one member IFNγ, which is primarily associated with antibacterial immunity. IFN-γ is primarily secreted 
by IL-12 induced Th1 T-cells. Individuals with deleterious mutations in the IL-12 receptor as well as mouse 
knockout studies of IFN-γ have shown that IFN-γ and IL-12 deficient subjects were more susceptible to M. 





Recent studies of the entire transcriptome of peripheral blood elucidated gene expression profiles 
in which type I/II IFN signalling pathways correlate with the latent and active forms of tuberculosis 
(Ottenhoff et al., 2012). The idea that type I/II signalling plays a role in mycobacterial pathogenesis is 
further supported by evidence from leprosy where Type II interferon has been shown to facilitate the 
upregulation of CAMP and DEFB4 mRNA via the vitamin D-dependent antimicrobial pathway as well as 
encouraged significant antimicrobial activity in human monocytes. These authors found that this protective 
effect was abrogated by the type I interferon which reduced mRNA levels of both antimicrobial peptides 
and antimicrobial activity (Teles et al., 2013).  
These observations suggest that interferon signalling could have a significant impact on 
mycobacterial immunity in the context of HIV-infected individuals. In both the acute and chronic phases 
of HIV numerous immunoregulatory cytokines, including the interferons, are deranged (Stacey et al., 2009). 
Of notable importance, particularly in light of the work done in leprosy, is type I interferon, which remains 
at elevated levels through to the chronic phase of infection (Stacey et al., 2009, Hardy et al., 2013).   
The fact that TB risk increases in HIV individuals prior to a significant depletion of the CD4 T-cell 
population implies that the loss of immune control of M.tb is at least partially independent of CD4 loss 
(Sonnenberg et al., 2005). Thus, the imbalance of type I/II interferon observed in the co-infected cellular 
milieu may be a contributing factor to the loss of host control and progression to TB disease. However, the 
exact mechanism by which HIV-induced type I interferon may alter host IFN-γ mediated TB control in 
HIV-1 positive individuals remains an important gap in knowledge in the field. 
We initially hypothesised that the basal expression of the transcripts of interest would be 
comparable in primary monocytes from healthy donors and THP-1 cells, making THP-1 cells a useful 
model for the study of this pathway and its modulators. Further, knowing that HIV infection induces an 
immune milieu that is skewed towards Type-I IFN, we hypothesised that this would result in decreased 
production of the Vitamin D-dependent antimicrobial peptides. As such, we hypothesised that exogenous 





to innate phagocytes ex vivo was expected to downregulate key antimicrobial peptides when compared to 
unstimulated or Type-II stimulated cells.  
Within the context of the Vitamin-D dependent antimicrobial protective pathway, the aim of this 
study was to assess the basal expression of CAMP, VDR, CYP24a1, CYP27b1 and DEFB4 relative to the 
reference gene GAPDH in the THP-1 cell line and primary CD14+ monocytes and determine how this 
expression was modulated by type I/II interferon. This was achieved utilising the optimised real-time PCR 
assays detailed in Chapter Two of this thesis. 
3.1 Methods and Materials 
3.1.1 Cells and Reagents 
3.1.1.1 THP-1 Cells 
THP-1 cells were stored, thawed and maintained as described in 2.2.1.1. Approximately 2 million 
cells were isolated and stimulated per condition (rhIFNγ (2000 IU/mL) and rhIFNα2a (2500 IU/mL) 
respectively) or left unstimulated for 24 hours at 37° C. Concentrations and duration of stimulation using 
interferon were based on the literature and previously experiments in our laboratory; the concentrations 
were chosen to reflect the physiological concentrations observed during peak viral and bacterial infection 
(Gomez et al., 2015, Herbst et al., 2011). 
3.1.1.1 PBMC Isolation 
Healthy-donor leukopaks were acquired from donors from the South African National Blood 
Service in Durban, South Africa. These donors were free from all known pathogens for which the South 
African National Blood Service screens. Buffy coats were layered onto an equal volume of Histopaque® 
(Sigma-Aldrich) and spun at 400 x g for 45 minutes. Human plasma was removed to a separate tube. The 
PBMC layer was removed to 45 mL Dulbecco's phosphate-buffered saline (DPBS) and spun at 300 x g for 





discarded, the cells were resuspended in 10 mL R10 and manually counted. PBMCs were then rested for 
two hours prior to CD14 positive selection of monocytes. 
3.1.1.2 CD14+ Cells 
Monocytes from the PBMC preparation were isolated via positive immunomagnetic selection using 
CD14 MicroBeads kit (Miltenyi Biotec, Germany). Briefly, PBMCs were counted before being spun down 
at 300xg for 10 minutes. The supernatant was completely removed via aspiration. The pellet was 
resuspended in MACS buffer (2mM ethylenediaminetetraacetic acid (EDTA), 1% HI-FBS in PBS) to 80 
µL per 107 total cells. 20 µL of CD14 MicroBeads was added per 107 cells. The sample was then mixed 
well and incubated at 2-8 °C for 15 min. After incubation, the cells were washed by adding 2 mL MACS 
buffer per 107 cells and spun at 300 x g for 10 minutes, after which the supernatant was completely aspirated. 
Cells were resuspended in 500 µL MACS buffer per 108 cells. MACS LS Separator Column was placed in 
the magnetic field and rinsed with 3 mL MACS buffer. The sample was placed in a MACS LS Separator 
Column and the cell suspension was allowed to pass through the column and the column washed three times 
with 3 mL MACS buffer. The column was then removed to separate collection tube and 5 mL MACS buffer 
was used to flush out CD14+ cells. 
Using the same protocol for THP-1 cells and primary monocytes, 2 million CD14+ cells were 
stimulated per condition (rhIFNγ (2000 IU/mL) and rhIFNα2a (2500 IU/mL) respectively) or left 
unstimulated for 24 hours at 37° C. Concentrations and duration of stimulation using interferon were based 
on previously conducted studies and are assumed to reflect the physiological concentrations observed 
during peak viral and bacterial infection (Gomez et al., 2015, Herbst et al., 2011). 
3.1.2 RNA Isolation and cDNA Synthesis 





3.1.3 Primers and Real Time PCR  
Primer selection and real-time PCR conditions were described in section 2.2.3. Biological replicates 
were performed in triplicate (for THP-1 cells) and three independent healthy donors were assessed (for 
primary monocytes).  Technical replicates were performed in duplicate for each condition and each target 
gene. 
3.1.4  Analysis of Gene Expression 
The basal expression of transcripts of interest was expressed relative to GAPDH using the relative 
standard curve method (Larionov et al., 2005). The impact of interferon stimulation on gene expression in 
THP-1 cells and CD14+ healthy patient monocytes was calculated relative to unstimulated controls using 
the Pfaffl equation and normalised to GAPDH (Pfaffl, 2001).  
The significance of relative gene expression between stimulation conditions was analysed using an 
ANOVA test in GraphPad Prism (version 6). Assumptions for ANOVA, normality and equal variance of 
residuals, were verified by a one-sample Kolmogorov-Smirnov test and Levene’s test respectively.  








Figure 30: Basal Expression of Transcripts of Interest Relative to GAPDH is Variable in THP-1 Cells and 
CD14+ Healthy Patient Cells. 
3.2.1 Comparison of basal expression level for transcripts of interest in THP-1 cells and primary 
monocytes 
 As shown in Figure 30, three genes (CAMP, VDR and CYP27b1) were detectable in both THP-1 
cells and unstimulated primary CD14+ monocytes.  CAMP and VDR were expressed at similar levels 
(relative to GAPDH) in THP-1 cells and monocytes.  Notably, CYP27b1 was expressed at a notably lower 
level (relative to GAPDH) in primary monocytes than in THP-1 cells. Also of note, CYP24a1 and DEFB 
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Figure 31: Modulation of Gene Expression via Type I (2500 IU/mL) /II (2000 IU/mL) Interferon 
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3.2.2 Impact of interferon stimulations on gene expression in THP-1 cells 
 As shown in Figure 31, THP-1 cells were stimulated with (rhIFNγ (2000 IU/mL) and rhIFNα2a 
(2500 IU/mL) for 24 hours. Relative to unstimulated controls, cathelicidin (CAMP) was significantly 
downregulated by both type I interferon (p=0.0201) and type II interferon (p<0.0001). CYP27b1 expression 
was significantly downregulated by type II interferon (p=0.0009) but not altered by type I interferon. 
Vitamin D Receptor (VDR) was not significantly modulated by either stimulation (p>0.05).  As discussed 






Figure 32: Modulation of Gene Expression via Type I (2500 IU/mL) /II (2000 IU/mL) Interferon 
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3.2.3 Impact of interferon stimulations on gene expression in primary CD14+ monocytes 
 As shown in Figure 32, healthy donor CD14+ monocytes were stimulated with (rhIFNγ (2000 
IU/mL) and rhIFNα2a (2500 IU/mL) for a period of 24 hours. Although significant effects due to interferon 
stimulation were detected, it is worth acknowledging that interpatient variability may be the major driver 
of differences between stimulations observed in our primary cell data. Despite this, cathelicidin (CAMP) 
was significantly up-regulated by type II interferon (p=0.0419) and not modulated by type I interferon. 
Beta-Defensin 2 (DEFB4) was significantly up-regulated by type II interferon (p=0.0342) and not 
modulated by type I interferon. CYP24a1 was significantly up-regulated by type II interferon (p=0.0043) 
and not modulated by type I interferon. CYP27b1 was significantly up-regulated by type II interferon 
(p=0.0016) and not modulated by type I interferon. Vitamin D Receptor (VDR) was not significantly 
modulated by either type I or type II interferon stimulation. 
3.3 Conclusions and Discussion  
The changing interferon environment observed in bacterial and viral coinfections may have a 
significant impact on the pathogenesis of the disease. Mouse and human studies which have examined the 
effect of type I interferon, IFN-β, on mycobacterial infection have observed increased bacterial loads as 
well as increased mortality (McNab et al., 2014, Teles et al., 2013, Bouchonnet et al., 2002). In the context 
of tuberculosis, protective host-mediated immune control of M. tb microbes can be partially attributed to a 
vitamin D-dependant antimicrobial pathway, which is under the regulation of type II interferon (IFN-γ) in 
monocytes and macrophages in healthy individuals (Modlin and Bloom, 2013, Rook et al., 1986, Sonawane 
et al., 2011, Teles et al., 2013). Previous studies have linked an increase in type I interferon with a decrease 
in the transcription of key antimicrobial peptides and a worsening of bacterial control (Shahangian et al., 
2009, Teles et al., 2013)  
 During acute HIV-1 infection, there is a global upregulation of multiple immunoregulatory 





scope of this study is the initial, and chronic, upregulation of the type I interferon, IFNα2a, which is not 
only measurable at elevated levels in the blood but is actively expressed by alveolar macrophages in the 
lung (Hardy et al., 2013, Kumagai et al., 2007). Previous studies on type I/II interferon imbalance have 
primarily focused on the effect of IFN-β, the key type I interferon upregulated during other notable viral 
infection such as influenza A (Shahangian et al., 2009, Teles et al., 2013). As such, the effect of IFNα2a 
within the context of protective immune control of mycobacterial/HIV coinfection remains a key gap in 
knowledge of this field since it is the key type I interferon was shown to be elevated in HIV-infected patients 
(Hardy et al., 2013). 
 In the current study, we measured the independent effects of recombinant IFNα2a and IFN-γ on 
the transcription of antimicrobial peptides (CAMP and DEFB4) and associated regulatory transcripts 
(VDR, CYP24a1 and CYP27b1) in the human monocytic cell line THP-1 and CD14+ monocytes. To our 
knowledge, a study looking at the effect of type I/II interferon imbalance, specifically in the context of 
HIV-1 induced IFNα2a has not been conducted in a South African cohort. Although limited by the small 
sample size, this study has provided interesting insights into the potential effects an imbalanced type I/II 
interferon immune milieu expected in HIV/TB coinfection. 
3.3.1 Expression of the pathway of interest differed in THP-1 cells and primary CD14+ monocytes 
The basal expression of a transcript of interest in a healthy cell can be used as a measure of its 
developmental state or its ability to quickly translate certain transcripts upon activation. In the current study, 
we have shown that healthy, uninfected CD14+ human monocytes and THP-1 cells, an immortalised 
monocytic cell line, differ in basal expression of key antimicrobial peptides and regulatory transcripts. Only 
two of five transcripts of interest demonstrated similar levels of baseline transcription (relative to the 
housekeeping gene) in THP-1 cells and CD14+ human monocytes.  CAMP and VDR were comparably 
expressed relative to GAPDH in both THP-1 cells and primary human monocytes.  One of the five 





1 cells.  Interestingly, in THP-1 cells the expression of CYP24a1 and DEFB4 was reproducibly 
undetectable. However, in primary CD14+ monocytes, CPY24a1 and DEFB4 were detectable, though at 
low levels compared to GAPDH and the other transcripts of interest.  
Our finding, that CYP24a1 and DEFB4 were undetectable in THP-1's has been noted in the 
literature (Liu et al., 2007, Adams et al., 2009, Gottfried et al., 2006).  Specifically, Adams et al (2009) and 
Gottfried et al (2006) were unable to detect DEFB4 and CYP24a1 in cells cultured in Vitamin D-deficient 
media.  However, when vitamin D was supplemented (100 nM) these authors were able to detect these 
transcripts.  Based on this, we think it likely that our results are due to culture in a vitamin D deficient 
environment.   
 Under the experimental conditions that we used (no vitamin D supplementation), it is clear that 
THP-1's were not a very good model for the study of this pathway in primary CD14+ monocytes.  This 
highlights the importance of testing any model system prior to assuming that it is reflective of ex vivo 
primary cells.  Based on these results, it might seem advantageous to solely study this pathway in primary 
cells, however, intra-patient variation would confound results and limit reproducibility. Although the work 
presented here did not solve this perennial problem, it does highlight the importance of interrogating cell 
lines for the measure of interest against the primary cells to understand the limitations of any given model 
system. 
3.3.2 Interferon gamma upregulated key immune factors in CD14+ monocytes and unexpectedly 
down-regulated some of the same factors in THP-1 cells 
Our results from healthy CD14+ monocytes showed significant upregulation of CAMP, DEFB4 
and CYP27b1 upon type II IFN (rhIFN-γ) stimulation; this is in agreement with previously published 
studies (Fabri et al., 2011, Teles et al., 2013). The upregulation of these transcripts implies the expected 
functioning of the vitamin D-dependent antimicrobial pathway within healthy patient CD14+ cells (see 





 In contrast, CAMP and CYP27b1 were downregulated by type II IFN stimulation in THP-1 cells.  
This was unexpected, but, as discussed above, our results showed notable differences between baseline 
levels of transcription of these genes in the cell line and primary monocytes.  It is possible that the 
downregulation of these two genes in THP-1 cells reflects vitamin D deficient conditions. Previous studies 
have shown the direct link between this vitamin and CAMP induction (see Figure 32 below) and linked 
vitamin D deficient conditions to dysfunction of this pathway (Gombart et al., 2005, Schauber et al., 2008, 
Gonzalez-Curiel et al., 2014). Along similar lines, our inability to detect DEFB4 and CYP24a1 in THP-1 
cells may also be attributed to vitamin D deficient conditions in THP-1 cells (Fabri et al., 2011). The 
potential effect of vitamin D availability will be further discussed in section 3.3.4 of this discussion. 
3.3.3 Interferon Alpha 2a stimulation did not significantly modulate the expression of key immune 
factors in CD14+ cells 
Exogenous Type I interferon (rhIFNα2a) stimulation of CD14+ cells revealed unexpected 
directionality of gene modulation. In healthy donor CD14+ cells, all genes with the exception of VDR 
showed a non-significant trend towards up-regulation after Type I IFN stimulation (see Figure 32 below).  
Exogenous Type I interferon (rhIFNα2a) stimulation of THP-1 cells resulted in downregulation of 
the pathway of interest. In THP-1 cells, exogenous rhIFNα2a stimulation resulted in the significant 
downregulation of CAMP and the non-significant trend towards downregulation of VDR and CYP27b1 
(see Figure 32 below). This result is similar to those found in studies that utilised IFNβ as the primary 
source of type I interferon (Teles et al., 2013).   
Though nonsignificant, the upregulation of the pathway in CD14+ monocytes is in contrast to the 
published literature which reports downregulation of this pathway upon in vitro stimulation with Type I 
IFN.  A possible explanation for this discrepancy could be differences in effect between IFNα2a and IFN-
β. Although both interferons bind the same cellular receptor, IFNAR1, they may have varying effects on 
the vitamin D-dependent antimicrobial peptides and regulatory transcripts.  Although it was beyond the 





different effects on this pathway in primary CD14+ cells. If confirmed, this line of investigation could have 
implications for the antimicrobial potential of these cells in the context of an overexpression of IFNα2a in 
HIV-1 infection.  
 That our findings contrast to those previously reported could also have a genetic explanation. 
Recent studies have highlighted the effect of genomic single nucleotide polymorphisms which vary between 
populations of European and African origin and alter the expression of genes (up to 9.3% in macrophages) 
involved with immune response and inflammation when challenged with microbial stimulants/agonists 
(Quach et al., 2016, Nedelec et al., 2016). In general, the majority of studies which have looked at the effect 
of type I/II interferon imbalance on this pathway have been performed in settings in which the healthy 
donors were likely of European ancestry (Adams et al., 2009, Fabri et al., 2011, Teles et al., 2013). Thus, 
healthy donors of African ancestry may elicit a different response to interferons and this area of research 
represents a significant and interesting gap in scientific knowledge and may to some extent explain the 
variability in our results compared to the literature.   Small sample size represents another important 
potential explanation for the differences observed in our study compared to the literature.  It is possible that 
with more independent donors, a significant modulation by IFNα2a would have been observed. To 
overcome both of these issues the next step would be to directly compare the gene modulation between and 
an appropriate number of donors of both African and European ancestry. 
 The non-significant modulation (towards upregulation) of CYP24a1 by IFNα2a in healthy donor 
CD14+ cells was an interesting observation particularly in the light of leprosy studies which found that 
upregulation of CYP24a1 was correlated with the expression of IL-4 at the site of lesions (Yamamura et 
al., 1991, Cooper et al., 1989). Within our South African healthy donor CD14+ samples, CYP24a1 was 
significantly upregulated via stimulation with IFN-γ - independent of CD4+ T cells implying a direct 
inductive effect via IFN-γ in the absence of IL-4. This interaction may be facilitated via a direct gene-to-
gene effect, however, it likely involves several other contributing factors and genes. Again, although this 





rhIFN-γ and exogenous IL-4 on CYP24a1 expression within primary monocytes. If confirmed, this may 
elucidate alternative regulatory pathways for vitamin D metabolism under the control of type II interferon 
and would have a direct effect on the protective vitamin D-antimicrobial response. More comprehensive 
hypothesis generating transcriptomic analyses, such as RNA-seq, may be useful avenues of experimentation 
to tease out unknown contributors to protection, regulation or sensitivity. 
The detection of CYP24a1 at the basal level in healthy donor CD14+ cells may be indicative of 
some form of catabolic vitamin D negative feedback mechanism of this protective pathway due to excess 
25 vitamins D3- as these healthy donors are assumed to be vitamin D replete.  
In summary, stimulation of healthy donor CD14+ cells with rhIFN-γ resulted in the upregulation 
of protective AMPs and key regulatory factors in support of our original hypothesis. Stimulation with 
rhIFNα2a, though non-significant, induced pathway genes in an unanticipated manner. In THP-1 cells, and 
in contrast to literature as well as our original hypothesis, rhIFN-γ unexpectedly downregulated key 
pathway genes and regulatory transcripts while rhIFNα2a had the anticipated negative modulation of the 
pathway. The expected results observed in this study may be as a consequence of vitamin D deficiency, the 
differing activity of IFNα2a vs. IFNβ, absent TLR 1/2 stimulation or population genetics.  
3.3.4 The role of Vitamin D may explain differing basal expression as well as unexpected programs 
of gene modulation between CD14+ cells and THP-1 cells 
One of the key findings of this study was the difference in transcription of key genes in the pathway 
of interest observed between THP-1 cells and primary monocytes. CYP24a1, as well as DEFB4, could not 
be detected in THP-1 cells. Culture in a vitamin D deficient cellular environment may have contributed to 
the lack of expression of DEFB4, which has been hypothesised to be induced by the binding of the bioactive 
form, 1, 25 vitamin D to the vitamin D receptor (VDR). Interestingly, HIV-infected persons worldwide 
have been found to suffer from chronic vitamin D deficiency which may hamper the expression of key 





cART is initiated (Mueller et al., 2010, Allavena et al., 2012). Fabri et al. found in their 2011 study that 
exposure to exogenous 1, 25D3 in conjunction with rhIFNγ stimulation significantly increased the 
expression of both CAMP and DEFB4 in human monocytes and macrophages by approximately 6 and 5.5 
fold respectively (Fabri et al., 2011). However, under vitamin D deficient conditions IFN-γ stimulation 
either significantly downregulated CAMP and DEFB4 or showed no significant difference to negative 
controls, a phenomenon observed in the THP-1 results of this study (Fabri et al., 2011). Similarly, in THP-
1 cells, Liu et al. found that expression of CYP24a1 was detectable only under culture conditions containing 
1, 25D3, a phenomenon which has been observed in several studies (Liu et al., 2007, Heulens et al., 2016).  
 Vitamin D metabolism plays an important role in our pathway of interest and varying levels of the 
bioactive forms of vitamin D in different samples may help to explain our findings.  The low levels of basal 
CYP27b1 and DEFB4 quantified in the CD14+ monocytes were unsurprising when taken in the context of 
a “healthy individual” who is assumed to be vitamin D replete. In the absence of inflammatory disease and 
the presence of sufficient vitamin D, the upregulation of vitamin D metabolism and antimicrobial pathways 
would not necessarily be required and would exist at a normal basal level. This interpretation of the data is 
further supported by the slight upregulation of VDR that we observed in CD14+ cells compared to THP-1 
cells; VDR upregulation is observed during physiological excess of bioactive vitamin D (Adams et al., 
2009).  
 In the experiments presented here, THP-1 cells were not supplemented with any form of Vitamin 
D. It is possible that in THP-1 cells, the upregulation of CYP27b1 and the undetectable expression of 
CYP24a1 and DEFB4 could be attributed the long-term culture of THP-1 cells in a Vitamin-D deficient 
environment. Adam et al. 2009 have reported similar data in human monocytes cultured in vitro under 
Vitamin-D deficient conditions resulting in the 5-fold upregulation of CYP27b1.  They hypothesised that a 
lack of the circulating form of Vitamin-D, 25-hydroxyvitamin D (25(OH)D3), prompted the upregulation 
of this gene in an attempt “prime” the cell for potential antimicrobial activity via the rapid scavenging of 





 The detectable basal expression of CAMP within THP-1 cells was an interesting finding in our 
experiments, as upregulation of CAMP and DEFB4 has been linked to the binding of 1, 25 vitamin D3 to 
the vitamin D receptor (VDR) (Adams et al., 2009, Fabri et al., 2011, Gombart et al., 2005, Heulens et al., 
2016). If the hypothesis of DEFB4 downregulation/loss in the face of vitamin D deficiency is correct, then 
the expression of CAMP in the absence of vitamin D implies a possible alternative pathway in THP-1 cells 
that maintain expression of CAMP even in Vitamin-D deficient conditions.   
The presence or absence of vitamin D may modulate the host immune response. In data shown in 
this study, it is likely that the unexpected results observed between THP-1 cells and primary monocytes 
may be as a consequence of vitamin D deficiency. The observed absence of induction of protective genes 
in THP-1 cells, that are cultured in a vitamin D lacking environment, is particularly interesting when taken 
in the context of HIV-1 infected individuals who are generally chronically vitamin D deficient and may 
explain sensitivity to TB disease. These observations raise interesting questions about antimicrobial peptide 
expression in the context of varying Vitamin D levels but go beyond the scope of this Master's project. 
However, to better elucidate the effect of vitamin D on this pathway the next steps would be the assessment 
of this protective pathway via the measurement and standardisation of vitamin D conditions in future in 
vitro and ex vivo studies. 
3.3.5 Overall Conclusions 
In conclusion, we assessed the basal expression of CAMP, VDR, CYP24a1, CYP27b1 and DEFB4 
in the THP-1 cell line and healthy donor CD14+ cells and found notable differences between expression 
levels of these transcripts in the two sets of cells (Figure 33).  CYP24a1 and DEFB4 were undetectable in 
the THP-1 cell line but detectable in primary monocytes and CYP27b1 was expressed at significantly higher 
levels relative to housekeeping genes in THP-1 cells compared to CD14+ cells. We hypothesise that these 
findings may be a consequence of the culture of the THP-1 cells in a Vitamin-D-deficient cellular 
environment.  We conclude that under the tested conditions, THP-1 cells have significant limitations as a 





 In terms of the effect of exogenous interferon stimulation, we have shown, despite the small sample 
size, several interesting outcomes relating to the effect of type I/II interferons on human monocytes. 
Stimulation of CD14+ cells ex vivo with rhIFNγ resulted in the up-regulation of key antimicrobial peptides 
and regulatory transcripts important in inducing a protective innate response against pathogenic microbes, 
while type I interferon (rhIFNα2a) had no significant effect on the expression of the same peptides in 
primary monocytes and THP-1 cells but showed an unanticipated trend towards upregulation of the 
antimicrobial peptides. The unexpected downregulation of transcripts of interest in THP-1 cells upon 
stimulation with rhIFNγ is hypothesised to be as a result of vitamin D deficiency, thus highlighting the 
importance of this vitamin in the context of this protective pathway.  
 
Figure 33: Summarised Effect of Type I/II Interferon on the Expression of Key Antimicrobial Peptides and 
Regulatory Transcripts of the Vitamin D-Dependent Antimicrobial Pathway in THP-1 cells and Healthy 
Patient CD14+ Monocytes. Black arrows/bars equate to modulation or no effect of Type II IFN (IFNγ) 
respectively. Purple arrows equate to modulation of Type I IFN (IFNα2a) respectively. *p<0.05 
This study was designed to examine the vitamin D-dependent antimicrobial pathway and the 
independent impact of type I/II interferon in monocytes. Results from this study have highlighted the 





transcripts.  Specifically, as discussed above, Vitamin D is almost certainly of central importance in this 
pathway.  Additionally, it is likely that other known modulators of the pathway -- like the TLRs -- are 
important.  In the complicated context of HIV infection and a disturbed inflammatory milieu, there may be 
additional other modulators of this pathway.  Nonetheless, this study confirms IFN-γ as an inducer of this 
pathway and raises many questions about the potential role of Type 1 IFN on this pathway and in the context 
of HIV infection.  Although much needs to be worked out, it seems clear that Vitamin D deficiency and 
HIV may together have a deleterious impact on this antimicrobial pathway in human monocytes.  The 
groundwork for further study of this important topic has been laid through the methodological  work 
 presented  here.
4 CHAPTER FOUR: General Discussion and Conclusions 
South Africa has one of the world’s highest incidents of both HIV and TB, with TB being the 
leading infectious killer of HIV-infected persons both within this country and worldwide (WHO, 2014, 
WHO, 2016a). Globally it is estimated that approximately one in three people is infected with M. tb, 
however, only a small portion (approximately 10%) of those who are infected will ever progress to active 
disease in their lifetimes (Rappuoli and Aderem, 2011, WHO, 2016a). Immunosuppressive conditions such 
as diabetes, TNF neutralisation therapies and, in particular, HIV infection, have all been linked to 
reactivation of TB disease in those who have suffered in the past as well as the novel pathogenesis of disease 
in immunosuppressed individuals (Barry et al., 2009).  
The large number of otherwise healthy latently infected individuals relative to those who progress 
to active TB disease, particularly in high TB burden countries such a South Africa, implies the presence of 
host-mediated protective mechanisms capable of inhibiting pathogenesis. This host driven control can at 
least be partially attributed to the Vitamin-D dependent antimicrobial pathway in monocytes and other 
phagocytes (Modlin and Bloom, 2013, Campbell and Spector, 2012, Chun et al., 2015, Liu et al., 2007). 
This protective pathway results in the downstream induction of the antimicrobial peptides CAMP and 





Regulation of this pathway is mediated by the presence of the type II interferon, interferon gamma 
which is primarily secreted by T helper cells during bacterial infection. Effective immune control of M. tb, 
therefore, requires a robust T-helper type 1 (Th1) immune response, which has both a direct anti-TB effect 
but also dictates the accompanying innate immune responses of macrophages and other antigen presenting 
cells. The importance of IFN-γ has been convincingly illustrated in mouse knockout models which have 
shown a significant increase in the sensitivity to M. tb infection as well as increased mortality.  
Conversely, it has been shown that type I interferon, which is secreted in response to viral infection, 
has the ability to abrogate the protective response of the Vitamin-D dependent antimicrobial pathway by 
downregulating key antimicrobial peptides facilitating a loss of immune control (Teles et al., 2013). This 
is true for most temporal viral infections such as influenza, however, chronic infection such as HIV have 
implications for TB pathogenesis (Redford et al., 2014). HIV-1 has been shown to be a potent inducer of 
numerous immunoregulatory cytokines which never return to baseline expression throughout the course of 
the disease (Stacey et al., 2009). Of particular importance for the Vitamin-D pathway is the chronic 
upregulation of the type I interferon, IFNα2a (Hardy et al., 2013). The quantification of the degree to which 
the antimicrobial peptides and associated factors are modulated by an unbalanced interferon milieu 
observed in TB/HIV coinfection was the ultimate goal of this study. 
The assessment of the vitamin D-dependent antimicrobial pathway requires a robust molecular 
toolkit for reliable quantification of key genes. In this study, a one plate real-time PCR assay for the accurate 
and reproducible detection of CAMP, VDR, CYP24a1, CYP27b1 and DEFB4 using SYBR green chemistry 
was optimised for use in THP-1 and primary cells. Primer pairs were bioinformatically validated and 
amplicons were run on a 2.5% agarose gel to ensure correct product sizes. Interesting, CYP24a1 and DEFB4 
were reproducibly undetectable in THP-1 cells and the primer pairs for each gene had to be optimised using 
a commercial reference RNA library made of 10 different human tissues which were later validated in 





long-term culture of the THP-1 cells in a Vitamin-D deprived environment, though this hypothesis still 
remains to be confirmed. 
The optimisation of a one plate real-time PCR assay for key genes in this protective pathway 
facilitated the assessment of both the basal expression levels of these genes as well as the independent effect 
of exogenous recombinant type I/II interferon stimulation on both THP-1 cells and healthy patient CD14+ 
monocytes. Basal expression levels revealed that CAMP, VDR and CYP27b1 were detectable in both THP-
1 cells and primary CD14+ monocytes.  CAMP and VDR were expressed at similar levels (relative to 
GAPDH) in THP-1 cells and monocytes.  Notably, CYP27b1 was expressed at a significantly lower level 
in primary monocytes than in THP-1 cells.  This may be explained by the vitamin D deficient culture 
environment where the cells are actively trying to ramp up their vitamin D metabolism. This result is in 
agreement with a study conducted by Adam et al. 2009 who noted a 5.5-fold increase in CYP27b1 in human 
monocytes cultured under vitamin D-deficient conditions. Also of note, CYP24a and DEFB continued to 
be undetectable in THP-1 cells but were detectable in primary CD14+ monocytes. 
The independent stimulation of THP-1 and CD14+ healthy patient monocytes with type I/II 
interferon displayed differing programs of gene modulation. In THP-1 cells, IFNα2a induced no significant 
effect on the three detectable transcripts of interest (CAMP, CYP27b1 and VDR) whilst stimulation with 
IFN-γ resulted in the unexpected down-regulation of CAMP and CYP27b1. In healthy donor CD14+ 
monocytes stimulated with IFN-γ, CAMP, CYP24a1, CYP27b1 and DEFB4 were all significantly 
upregulated. IFNα2a resulted in a trend towards up-regulation of CAMP, CYP24a1, CYP27b1 and DEFB4.  
VDR expression was not modulated by either Type I or II interferon stimulation in healthy donor 
monocytes. 
In conclusion, I have developed a one plate real-time PCR assay for the accurate quantification of 
CAMP, VDR, CYP24a1, CYP27b1 and DEFB4 – key genes in the vitamin D-antimicrobial pathway. 
Utilising this optimised assay, and despite a small sample size (n=3), I discovered notable differences in 





Further, exogenous recombinant type I/II interferon stimulation of THP-1 cells and patient monocytes also 
displayed varying programs of gene modulation. Primarily, ex vivo stimulation of healthy patient primary 
monocytes with type II interferon (rhIFNγ) resulted in the up-regulation of key antimicrobial peptides and 
regulatory transcripts important in inducing a protective innate response against pathogenic microbes. 
Unexpectedly, type I interferon (rhIFNα2a) had no significant effect on the expression of the same peptides 
in primary monocytes and THP-1 cells but showed an unanticipated trend towards upregulation of the 
antimicrobial peptides, CAMP and DEFB4. The unexpected downregulation of transcripts of interest in 
THP-1 cells upon stimulation with rhIFNγ is hypothesised to be as a result of vitamin D deficiency, thus 
highlighting the importance of this vitamin in the context of this protective pathway, particularly in light 
patient samples, however, this hypothesis remains to be confirmed. Further, we have demonstrated an 
impaired ability of THP-1 cells to amplify DEFB4 in vitro implying a key disadvantage for the use of this 
cell line as a model for relevant antimicrobial activity studies as well highlighting key differences between 
cell lines and primary cells.  
 
5 CHAPTER FIVE: Limitations and Future Studies  
The specific limitations observed in this study, and potential solutions to overcome these limitations in 
the future, have been mentioned in the discussion sections of Chapters 2 and 3 above. However, in short, 
additional experiments, using an appropriately large data set, and next steps should focus on; 
x Evaluating the effect of bioactive vitamin-D on this antimicrobial pathway by; a) quantifying 
its concentration in plasma and b) conducting stimulation experiments with/without exogenous 
bioactive vitamin-D. 
x Evaluating the effect of activation through the stimulation of TLR 1/2 using appropriate ligands 





x Using hypothesis generating technologies such as RNA-seq and high throughput gene 
expression assays such as Fluidigm, additional novel gene targets may be identified to be tease 
out the cellular mechanism involved in this pathway. 
Long term, this study has laid the groundwork by establishing a set of assays and applying them to 
healthy human monocytes.  A clear next step will be to apply these assays to the peripheral blood and tissue 
resident macrophages of HIV-infected and HIV-uninfected donors.  Future studies into the imbalance of 
type I/II interferon observed during HIV/TB coinfection and its effect on the antimicrobial ability of 
monocyte/macrophages should control for exogenous bioavailable vitamin D and examine the potential of 
TLR1/2 activation using live M. tb as well as infectious HIV-1 in-vitro. This will facilitate more 
physiologically relevant conclusions and lead the way for confirmatory ex vivo studies of coinfection in 
primary cells from both the periphery and tissue samples (alveolar macrophages).  
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APPENDIX  
Appendix 1: Conditions for the design of an Optimal Primer Pair for Specific Amplification 
Parameter Optimum Conditions 
Primer Length 19 – 25 bp 
Amplicon < 400bp 
Spanning Exon – exon spanning 
Stability 3’ end stable 
GC Content 20 – 70% 
Melting Temperature Sense and Antisense Primers should be comparable 





Appendix 2: Primer-BLAST Alignments of Final Selected Primer-Pairs: A) CAMP, B) VDR, C) CYP24a1, 











Appendix 3: Additional Gene and Primer Information 





Primer-Pairs GC % Tm (°C) Amplicon 
Size (bp) 
Cathelicidin CAMP NM_004345.4 2145 3p21.3 F 5' CCAGGACGACACAGCAGTCA 3' 60.00 62.09 59 
R 5' CTTCACCAGCCCGTCCTTC 3' 63.16 60.38 
Vitamin D Receptor VDR NM_000376.2 63495 12q13.11 F 5' AGGCTGCAAAGGCTTCTTC 3' 52.63 58.35 135 
R 5' ATGTCCACACAGCGTTTGAG 3' 50.00 58.77 
Cytochrome P450 Family 24 
Subfamily A Member 1 
CYP24a1 NM_000782.4 20529 20q13 F 5' CGCAGCGGCTGGAGAT 3' 68.75 59.45 61 
R 5' CCGTAGCCTTCTTTGCGGTA 3' 55.00 60.11 
Cytochrome P450 Family 27 
Subfamily B Member 1 
CYP27b1 NM_000785 4860 12q14.1 F 5' TCCATCCTGGGAAATGTGACA 3' 47.62 59.01 233 
R 5' ACAGGGTACAGTCTTAGCACTT 3' 45.45 58.75 
Beta-Defensin 2 DEFB4 NM_004942.3 2039 8p23.1 F 5' GGTGTTTTTGGTGGTATAGGCG 3' 50.00 59.84 75 
R 5' AGGGCAAAAGACTGGATGACA 3' 47.62 59.57 
Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH NM_002046.5 3953 12p13 F 5' AAGGTCGGAGTCAACGGATT 3' 50.00 59.03 225 
R 5' CTCCTGGAAGATGGTGATGG 3' 55.00 57.37 
Ubiquitin C UBC NM_021009.6 2594 12q24.31 F 5' TTTCCAGAGAGCGGAACAG 3' 52.63 57.09 202 
R 5' TCACGAAGATCTGCATTGTCAAG 3' 43.48 59.32 
Beta Actin ACTB NM_001101.3 3454 7p22 F 5' GATCAAGATCATTGCTCCTCCTG 3' 47.83 58.93 121 
R 5' GCCGGACTCGTCATACTCC 3' 63.16 59.64 
 
